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Abstract 33 
Ethnopharmacological relevance: Plant materials are used worldwide as complementary 34 
and alternative therapeutics for the treatment of various illnesses. In Ethiopia, folk medicines are 35 
utilized across a wide range of cultures and settings. Ethiopia has numerous plant species of which 36 
around 12% are endemic, making it a rich source of medicinal plants that are potentially important for 37 
human wellbeing. 38 
Aim of the study: The aim of this study was to assess Ethiopian medicinal plants with anti-39 
inflammatory or wound healing activities, in an attempt to compile the information required for further 40 
investigation of their potential role in the management of lymphoedema.  41 
Methods: A systematic review protocol was developed according to the preferred reporting items for 42 
systematic review and meta-analysis protocols (PRISMA-P) statement. The protocol for this review 43 
was registered on PROSPERO with registration number CRD42019127471. This review considers all 44 
controlled in vivo and in vitro anti-inflammatory and wound healing studies evaluating the efficacy and 45 
safety of Ethiopian medicinal plants.  The search strategy included all articles containing descriptors 46 
such as Ethiopia, medicinal plants, herbal products, care, management, lymphoedema, lymphedema, 47 
swelling, podoconiosis, elephantiasis, wound, wound healing, inflammation, and anti-inflammatory that 48 
were published up to June 28, 2019. Outcomes were measured as the percentage of inflammatory and 49 
pro-inflammatory cell inhibition, as the percentage of carrageenan-induced oedema (anti-inflammation) 50 
inhibition, and the percentage of cell migration and proliferation (wound healing). For quality 51 
assessment of individual animal studies, the Risk of Bias tool for animal intervention studies 52 
(SYRCLE’s RoB tool) criteria was used. For quality assessment of individual in vitro studies, the 53 
OECD guidelines and the WHO Good Laboratory Practice (GLP) handbook were used.  54 
Results: A total of 46 articles on anti-inflammatory and 17 articles on wound healing properties were 55 
reviewed. For the in vivo studies, Swiss albino mice and Wistar rats were used, and the concentration 56 
of plant extracts or fractions administered to the lab animals varied considerably. Acetone extract of 57 
Vernonia amygdalina showed the fastest anti-inflammatory activity at lower concentrations in 58 
carrageenan-induced paw oedema.  59 
Conclusion: Lawsonia inermis, Azadirachta indica, Achyranthes aspera, and Cuminum cyminum are 60 
the most studied plant species in terms of anti-inflammatory activity, while Lawsonia inermis and 61 
Azadirachta indica are the most studied for wound healing. The most common in vivo techniques used 62 
for the anti-inflammatory and the wound healing assays were carrageenan-induced paw oedema, and 63 
excision and incision wound models, respectively.  64 
Key words: Ethiopian, Medicinal plants, anti-inflammatory, wound healing, systematic review 65 
 66 
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1. Introduction 101 
 102 
Traditional herbal medicines are important across a range of societies and continue to be used 103 
globally as alternative and complementary treatments for a range of disease conditions.  They 104 
have immense importance for the health of individuals and communities through the secondary 105 
metabolites of the plants that induce biological changes in the body (Mohammad et al., 2013). 106 
Presently, there is great interest in medicinal plant research to obtain compounds that have a 107 
range of pharmacological activities. Currently, most conventional drugs used for a range of 108 
diseases arise from natural sources (Mathew et al., 2008).  109 
Looking for viable and affordable medications, molecules obtained from plants represent an 110 
appealing alternative (Pan  et al., 2013). Medicinal plants are comparatively non-toxic and are 111 
composed of complex molecules with various potential targets and multiple mechanisms of 112 
action (Hopkins et al., 2006). Secondary metabolites found in medicinal plants have been 113 
reported to have analgesic and anti-inflammatory activities (Mohammad et al., 2013). Most of 114 
these metabolites act on cellular processes that cascade inflammation in a similar manner as 115 
conventional anti-inflammatory drugs (Joseph et al., 2010). There are also reports of herbal 116 
products used for the management of wound healing, which implies that they may be suitable 117 
and cheap to use (Mulisa et al., 2015).   118 
The situation is similar in Ethiopia, where traditional medicine is normally established in all 119 
societies (Lulekal et al., 2014). In Ethiopia, the practice of traditional medicine has been in 120 
place in rural areas for a long time, and many Ethiopian medicinal plants are claimed to have 121 
anti-inflammatory and wound healing activities (Gebremeskel et al., 2018). However, data on 122 
the safety and efficacy of Ethiopian medicinal plants evaluated for their anti-inflammatory and 123 
wound healing activities have not previously been summarized.  124 
Thus, there is a need to investigate the potential therapeutic merits of Ethiopian endemic plants 125 
for a range of disease conditions. One of these is lymphoedema, whose management includes 126 
reduction of acute attacks and treatment of inflammation and wound infections. This 127 
pathological condition is classified into primary or secondary. Primary lymphoedema arises 128 
from genetic disorders, and secondary lymphoedema from damage to the lymphatic system, 129 
due to lymphatic vessel infestation, lymphadenectomy or radiotherapy in cancer patients 130 
(Geroulakos et al., 2007; Lisovoski, 1986).  Filariasis is the main cause of tropical 131 
lymphoedema, followed by podoconiosis (non-filarial elephantiasis) (Lisovoski, 1986).  132 
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Furthermore, recurrent bacterial cellulitis can also result in lymphoedema (Al-niaimi and Cox, 133 
2009).  134 
Inflammation is a complex pathophysiological process mediated by a wide range of signaling 135 
molecules produced by leukocytes, macrophages and mast cells as well as by the activation of 136 
complement factors resulting in extravasation of fluid and proteins and accumulation of 137 
leukocytes at the inflammatory site (Mohammed et al., 2014). 138 
Non-steroidal anti-inflammatory drugs are the most widely used medications for the 139 
management of pain and inflammation, although they are often associated with adverse effects 140 
such as gastrointestinal ulcers and hemorrhage (Bribi et al., 2015). Long-term use of steroidal 141 
anti-inflammatory drugs may have severe adverse reactions leading to cardiovascular, 142 
endocrine, metabolic, musculoskeletal, and ophthalmologic problems (Chester et al., 2017).  143 
Plant materials are claimed to be alternative remedies for the management of pain and 144 
inflammation, with fewer side effects (Bribi et al., 2015).   145 
The purpose of managing lymphoedema is to improve lymphatic flow and reduce ‘acute 146 
attacks’, which can be achieved through a range of approaches (Jullien et al., 2011). A 147 
pharmacological approach is one option to treat acute inflammation and infections, while 148 
traditional medicines are widely used for the management of pain and infections (Pan et al., 149 
2013).  150 
Preclinical studies have been conducted on the toxicity and effectiveness of Ethiopian 151 
medicinal plants against inflammation and wound healing. However, the effectiveness and 152 
toxicity profile of these plants in the management of limb conditions have never been 153 
documented.  154 
This systematic literature review aims to summarize information related to Ethiopian medicinal 155 
plants found to have anti-inflammatory and/or wound-healing properties in in vitro and in vivo 156 
studies. 157 
2. Methodology 158 
 159 
Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines were followed 160 
for the conduct and report of this systematic literature review (Moher et al., 2016). The protocol 161 
for this review was registered on PROSPERO with registration number CRD42019127471.  162 
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2.1.Study design 163 
 164 
This review considered pre-clinical studies conducted on anti-inflammatory and wound healing 165 
activities of Ethiopian medicinal plants. The component population (disease model), exposure 166 
(intervention), comparator and outcome (PICO) of this review are as follows:  167 
Study subjects (disease model) were laboratory animals, and cell lines used for in vitro studies. 168 
Medicinal plants as whole or their adjuncts: seed, root, flower, bud and leaf extracts used in 169 
the experimental groups were considered as interventions. Medicinal plants used were 170 
manufactured from single or complex medicinal plants, plant extracts, and plant preparations, 171 
regardless of their preparation (extracts, decoctions, tablets, capsules, pills, powders, 172 
injections, or other types of preparations), but not synthesized compounds. There were no 173 
restrictions on dosage form, concentration, frequency of administration, dose, intensity, or 174 
duration of medicinal plants used.  175 
Placebo, vehicle and drugs used for the treatment of controls were considered as comparators. 176 
Vehicles were not expected to produce an effect, but helped to identify outside influences on 177 
the experiment, such as contamination. Similarly, for placebo (non-intervention), control 178 
groups did not receive a treatment or were given an inert substance. The essential outcomes 179 
were effectiveness of medicinal plants (at safe concentrations) in reducing symptoms of 180 
inflammation in experimental animals, in wound contraction and healing, in comparison with 181 
reference drugs. In addition, in in vitro studies, down-regulation of inflammatory and pro-182 
inflammatory cells, cell proliferation and migration rate (wound healing) in µg/ml and mg/ml; 183 
minimum effective dose in 50% of the population (ED50), and minimum lethal dose in 50% of 184 
the population (LD50). Secondary outcomes were data on liver function tests, organ 185 
histopathology results (as a surrogate indicator for long-term toxicity) and mortality.  186 
2.2. Eligibility criteria 187 
 188 
Inclusion criteria:  Published works in English including theses, articles, and proceedings up 189 
to June 28, 2019, that dealt with anti-inflammatory or wound healing activities in in vivo or in 190 
vitro studies. 191 
Exclusion criteria: Newspapers and reviews  192 
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2.3.Information sources, searching and selection of studies 193 
 194 
Electronic databases such as Scopus, Embase, PubMed/Medline and Google Scholar were used 195 
as sources of information for the search. Grey literature such as theses, technical reports, 196 
working papers, evaluation reports, conference proceedings, patents, and preprints were also 197 
considered for the review. The search technique involved all available articles containing 198 
descriptors until June 28, 2019. Only published works written in English were used in this 199 
study. Structured search strategies were created using the lexical terms of each database and 200 
targeting the “title” and “abstract” fields. Manual searching was also employed using 201 
references to previously published works. Search terms such as Ethiopia, medicinal plants, 202 
herbal products, care, management, therapeutic, lymphoedema, swelling, podoconiosis, 203 
elephantiasis, wound, wound healing, inflammation, anti-inflammatory and other related words 204 
or phrases were used.  205 
After looking at the electronic database, all records were transferred to Mendeley referencing 206 
software. Studies were pilot-screened before undertaking full study selection. All articles were 207 
screened independently by two investigators (DNW and TBT) by skimming the titles and 208 
abstracts of the articles based on the criteria. For articles that met the inclusion criteria, 209 
investigators read the full document to check the inclusion criteria.  210 
2.4.Data extraction 211 
 212 
Two investigators (DNW and TBT) independently extracted data using a data extraction form. 213 
Initial calibration exercises were performed to ensure uniformity across the reviewers. The 214 
following data were extracted: title, author, year of publication, type of study (in vivo or in 215 
vitro), statistical methods used, type of animals used, age and weight of animals, study duration, 216 
number of animals used for the study, route and time of administration; dose/kg, reference 217 
drugs used; techniques used to induce inflammation or wounds; concentration at which 218 
inflammatory cells were down-regulated or inhibited paw oedema formation; minimum 219 
concentration that was toxic to 50% of cells (CC50), type of solvent extracts and fractions used 220 
for activity and safety, parts of plant used, extraction type, sources of the plants, place of 221 
collection, traditional use, scientific names of the plants, local names of the plants, voucher 222 
numbers, types and number of compounds isolated (if any). When separate studies had several 223 
treatment groups, the groups were combined to avoid presentation bias caused by different 224 
statistical comparisons with one control group (Moher et al., 2016).  225 
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2.5.Outcomes measured 226 
For the anti-inflammatory studies on laboratory animals, the key outcomes were the number of 227 
animals responding to treatment with the medicinal plant extracts, fractions and compounds, 228 
where response was defined as the percentage of carrageenan-induced oedema inhibition 229 
and/or the weight of granuloma tissue formation relative to the control group. For the in vitro 230 
studies of anti-inflammatory activity, the primary outcomes were percent inhibition of 231 
inflammatory cells and pro-inflammatory cells, defined as percent inhibition of the enzyme 232 
lipoxygenase, % inhibition of protein denaturation, levels of inflammatory substances (TNFα, 233 
IL6, IL10, and IFN-γ) produced by cells, levels of COX-2 counteracting antibody and levels 234 
of nitric oxide (NO) in inflammation-induced cell lines after subsequent treatment with plant 235 
extracts. The type of data (variables) extracted for anti-inflammatory and wound healing 236 
activities were continuous (percentage and pg/ml, µg/ml).  237 
In wound healing assays involving lab animals, the key outcomes were percentage shrinkage 238 
of wound area, time of epithelization and percentage of tensile strength in experimentally 239 
induced wounds, whereas for the in vitro wound healing studies, relative cell scattering and 240 
movement, percent cell propagation and viability were the key outcomes assessed.  Secondary 241 
outcomes were long-term effect of plant material, death of animals and experimental dropouts.  242 
2.6. Assessment of risk of bias 243 
 244 
Two investigators (DNW and TBT) independently evaluated the risk of bias for each included 245 
study. The critical appraisal process for studies involving lab animals was performed using the 246 
Risk of Bias tool for animal intervention studies (SYRCLE’s RoB tool) and Animal Research: 247 
Reporting of In vivo Experiments (ARRIVE) guidelines to evaluate the internal soundness of 248 
the studies (Connor and Sargeant, 2014; Hooijmans et al., 2014; Kilkenny et al., 2010). A “yes” 249 
decision showed a low risk of bias; a “no” decision indicated a high risk of bias; the judgment 250 
was considered “unclear” if inadequate details were reported to estimate the risk of bias 251 
properly. Studies were evaluated for their internal and external soundness. Reviewers judged 252 
the risk of bias for separate elements from five domains of bias (selection, performance, 253 
attrition, reporting, and others) using the Cochrane Risk of Bias Tool Appendix D and decided 254 
the inclusion and exclusion of the studies (Hooijmans et al., 2014) ( Supplementary 1). Then, 255 
the risk of bias criteria was referred to as ‘low’, ‘high’ or ‘unclear’. Studies with a low and 256 
moderate risk of bias were reported, whereas a high risk of bias studies was omitted from the 257 
analysis. 258 
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 259 
2.7.Data synthesis 260 
 261 
All studies included in the data synthesis were categorized into four separate investigational 262 
models as per the kind and aim of the studies: in vivo anti-inflammatory, in vitro anti-263 
inflammatory, in vivo wound healing and in vitro wound healing models. Heterogeneity was 264 
assessed descriptively from the narrative synthesised data, and potential reasons for 265 
heterogeneity were found by examining individual study and subgroup characteristics.  266 
Interventional, methodological and statistical heterogeneity existed between the studies, so 267 
statistical pooling of studies and meta-analysis could not be performed.   268 
Instead, a narrative (qualitative) summary of the studies was performed using textual 269 
descriptions of studies, grouping, and tabulation. Then, a description of the characteristics of 270 
the studies compared the effect of each plant extract relative to controls, the main parameters 271 
measured/analysed, quality of included studies and the risk of bias of all studies were described. 272 
This has also been described in our systematic review protocol (Nigussie et al., 2020).  273 
2.8.Main parameters analysed for in vivo and in vitro anti-inflammatory assays 274 
The main parameter used to analyse the activity of plant extracts for carrageenan-induced paw 275 
oedema (for acute inflammation) was the paw volume. After oral administration of the plant 276 
extracts or fractions to the test, reference and control groups, the volume of injected paws was 277 
measured before and after the injection of the inflammation-inducing agent (carrageenan) by 278 
measuring the linear paw circumference of oedematous legs using a plethysmometer or digital 279 
caliper. Alternatively, the volume of oedema was measured using the water displacement 280 
method, where the volume of water displaced corresponded to the volume of oedema. Then, 281 
the anti-inflammatory activities of plant materials were expressed as percentage and calculated 282 
using the following formula: 283 
% Inflammation (I) = 𝑉𝑉𝑉𝑉−𝑉𝑉𝑉𝑉   
𝑉𝑉𝑉𝑉
𝑥𝑥100(Tadiwos et al., 2017) 284 
Vi is the paw volume before carrageenan injection and Vf is the volume of paw after 285 
carrageenan injection at a given time. 286 
Similarly, percent 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 − 𝑎𝑎𝑎𝑎𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖𝑎𝑎𝑎𝑎𝑖𝑖𝑖𝑖𝑖𝑖 =  %𝐼𝐼𝐼𝐼−%𝐼𝐼𝐼𝐼
%𝐼𝐼𝐼𝐼
𝑥𝑥 100 287 
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where %Ic and %Ie are the mean inflammation values reached in the control and experimental 288 
groups, respectively.  289 
For sub-acute or chronic inflammation, autoclaved cotton pellets were aseptically implanted 290 
subcutaneously in the axillary region of rats anesthetized with diethyl ether. Extracts were 291 
administered once daily for 7 days. On day 8, the animals were anesthetized, and cotton pellets 292 
were removed surgically, freed from extraneous tissue and dried in an oven overnight at 60 °C. 293 
The dried pellets were weighed and the mean weight of granuloma tissue around each pellet 294 
was determined. The percent inhibition of granuloma tissue development was calculated using 295 
the formula: 296 
 (Tc –Tt)/Tc ×100, where Tc = weight of granuloma tissue of control groups Tt = weight of 297 
granuloma tissue of treated groups (Sharma and Rajani, 2011).  298 
Many methods were used to measure the anti-inflammatory activity of plant material in the in 299 
vitro model. The main parameters measured in the studies included were percent inhibition of 300 
production of cyclooxygenase enzymes (COX-1 and COX-2), inflammatory biomarkers such 301 
as vascular cell adhesion molecule-1 (VCAM-1), interferon gamma-induced protein 10 (IP-302 
10), interferon-inducible T-cell and chemoattractant (I-TAC), and monokine induced by 303 
interferon (MIG), nitric oxide (NO) production, IL-1𝛽𝛽 and IL-6 mRNA expression; quantity of 304 
pro-inflammatory cytokines (TNFα and IL-6), median inhibitory concentration (IC50) values, 305 
percent inhibition of protein denature and gene expression of inflammatory cells.  306 
2.9.Main parameters analysed for the in vivo and in vitro wound healing assay 307 
The main parameters measured in the in vivo wound healing studies were percentage wound 308 
contraction, histopathological studies (collagen formation, fibroblast proliferation and 309 
angiogenesis), percent tensile wound strength (skin breaking strength), period of epithelization 310 
(number of days required for complete falling of scab without any residual raw wound) after 311 
the treatment of incision and excision wounds with plant extracts and standard drugs. The 312 
parameters were calculated using the following formulae: 313 
% Wound contraction= (Healed area (mm2))/ (Original wound area) *100 314 
Where healed area = original wound area – present wound area. 315 
% Tensile strength (TS) of test sample = ((TS of test sample- TS so))/ (TS so) x 100 316 
% Tensile strength (TS) reference = ((TS of reference-TS So))/ (TS So) x100 317 
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% Tensile strength (TS) of So = ((TS So-TS Lu))/ (TS Lu) x 100 318 
where, So and Lu stands for simple ointment treated and left untreated groups, respectively. 319 
Several methods were used to measure the outcomes of wound healing. For wound contraction, 320 
wound areas were measured at different time intervals using a transparent sheet and a 321 
permanent marker.  The period of epithelization was measured by the number of days required 322 
for sloughing of the dead tissue, and the tensile strength of the wounds was measured using the 323 
continuous water flow method.  Histopathological characteristics such as hydroxyproline 324 
content, content of collagen formation, fibroblast proliferation and angiogenesis were 325 
measured.  326 
For the tests and controls, plant extracts and standard drugs were applied until the wound healed 327 
(for excision wounds) or for 10 to 11 days (for incision wounds). Measurement of treatment 328 
effect (end point) of wound contraction was conducted on a daily basis for 10 - 11 days, while 329 
the period of epithelization and tensile strength were measured on the 10th and 11th days (most 330 
studies) or every other day (in some studies) after the application of plant extracts and standard 331 
drugs.  332 
The main parameters measured in the in vitro wound healing assay were cell migration and 333 
proliferation and IC50 values for radical scavenging activity. Cytotoxicity assays were 334 
conducted for all medicinal plants, and all concentrations used for activity were safe to the cell 335 
lines used for the tests. In the first study, aqueous extracts of seventeen medicinal (Hooijmans 336 
et al., 2014) plants were studied using a wound healing scratch assay in 3T3 fibroblasts cell 337 
lines. The outcome measured after 21h of exposure to test and reference substances was cell 338 
migration and proliferation using a Leica DMLS microscope at 4x magnification before and 339 
after incubation to estimate the proliferation and migration of cells. Then, cell 340 
proliferation/migration rate was calculated as percent closure of the linear scratch made within 341 
21h, as shown below: 342 
(Cell migration)/ (Cell proliferation) = ((gap distance t0 - gap distance t21))/ (gap distance t0) x 343 
100 344 
t 0 = at time zero, t 21= time after 21 hr 345 
2.10. Quality of studies in vivo and in vitro anti-inflammatory assay (bias 346 
analyses) 347 
 348 
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The critical appraisal process for in vivo anti-inflammatory activity was performed using the 349 
Risk of Bias tool for animal intervention studies (SYRCLE’s RoB tool) and ARRIVE (Animal 350 
Research: Reporting of In Vivo Experiments) guidelines to assess the validity of scientific 351 
findings (Hooijmans et al., 2014; Kilkenny et al., 2010). Studies with high levels of bias were 352 
excluded. However, the studies included still have some weaknesses in their methodology. 353 
External and internal validity of the studies were evaluated. In external validity evaluation 354 
using animals as models for basic biological functions, the implication is that the results could 355 
be extrapolated to humans (Connor and Sargeant, 2014).  356 
We categorized the judgment of bias as yes, no or unclear.  A “yes” judgment indicated low 357 
risk of bias; a “no” judgment indicated high risk of bias; the judgment was “unclear” if 358 
insufficient details had been reported to assess the risk of bias properly. 359 
Under internal validity, the following ten main criteria were used: (1) adequate generation and 360 
application of the allocation sequence, (2) similarity of the control and test groups at baseline, 361 
(3) adequate concealment of allocation to different groups, (4) random housing of the animals 362 
during the experiment, (5) blinding caregivers and/or investigators to knowledge of which 363 
intervention each animal received during the experiment, (6) random selection of animals for 364 
outcome assessment, (7) blinding the outcome assessor, (8) adequate addressing of incomplete 365 
outcome data, (9) outcome reports from selection bias, and (10) absence of high risk of bias.  366 
The critical appraisal process for in vitro anti-inflammatory activity was performed using the 367 
Guidance Document on Good In Vitro Method Practices (GIVIMP) in vitro Studies (CRIS) 368 
guidelines.  369 
For the in vitro studies, quality assessment was based on seven main criteria which were 370 
extracted from these guidelines:  (1) quality assurance of all materials and methods, and their 371 
use and application, in order to maintain the truthfulness, soundness and reproducibility of 372 
laboratory  work conducted; (2) appropriateness of the in vitro cell and tissue culture facilities 373 
for purpose and a detailed understanding of the work flow for the  in vitro methods and related 374 
processes;  (3) apparatus, materials and reagents; (4) cell lines, media and serum, (5) test 375 
substance and reference/control items, (6) performance of the experiment, and (7) data analysis 376 
and interpretation. Under each criterion there are 2-8 sub criteria to evaluate the internal 377 
validity of the studies.  378 
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The judgment of bias was categorized as yes, no or unclear.  A “yes” judgment indicated low 379 
risk of bias; a “no” judgment indicated high risk of bias; judgment was “unclear” if insufficient 380 
details were reported to assess the risk of bias properly. 381 
2.11. Quality of in vivo and in vitro wound healing studies (bias analyses) 382 
The critical appraisal checklist we used for in vivo wound healing studies was similar to the in 383 
vivo anti-inflammatory activity. The Risk of Bias tool for animal intervention studies 384 
(SYRCLE’s RoB tool) and ARRIVE (Animal Research: Reporting of In Vivo Experiments) 385 
guidelines were used to assess the external and internal validity of the studies. Similarly, the 386 
judgment of biases was categorized as yes, no or unclear (Connor and Sargeant, 2014; Kilkenny 387 
et al., 2010).  The quality of these two studies was evaluated using the method and guidelines 388 
used in vitro anti-inflammatory studies. The Guidance Document on Good In Vitro Method 389 
Practices (GIVIMP) (Antonelli et al., 2018), and the Checklist for Reporting In vitro Studies 390 
(CRIS) guidelines (Krithikadatta et al., 2019), were used for the internal quality test of the 391 
studies. As above, the quality of the studies was evaluated based on seven main criteria. The 392 
judgment of biases was categorized as ‘yes’, ‘no’ or ‘unclear’ under each criterion; and based 393 
on this judgment, studies were either included or excluded in data extraction.  394 
3. Results  395 
 396 
3.1.Literature search results and description of study characteristics 397 
 398 
A total of 1297 relevant articles were independently identified by two reviewers for preliminary 399 
review from electronic and manual searches. Of these, 649 were from PubMed/Medline, 314 400 
from Embase, 38 from Scopus, 3 from Google Scholar, and 293 from other sources. After 401 
removal of duplicates by reviewing relevant titles and abstracts, a total of 153 articles were 402 
retrieved for full text review. After a detailed review of each article, 90 articles were excluded 403 
and 63 articles were retrieved: in vivo anti-inflammatory (n=31), in vitro anti-inflammatory 404 
(n=15), in vivo wound healing (n=15), and in vitro wound healing (n=2) studies (Figure 1).  405 
 406 
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Figure 1 - Flow Diagram of the in vivo and in vitro anti-inflammatory and wound healing 407 
literature search results 408 
 409 
3.2.Excluded studies  410 
 411 
Many studies have been conducted in these areas. However, most of the articles were not 412 
eligible for inclusion. The reasons for exclusion are given as follows:  413 
• Incomplete information:  414 
 The concentration of plant extracts used for activity and the number of 415 
experimental duplicates were not reported. 416 
 The method of outcome measurement was not reported. 417 
 Negative and positive controls used were not reported. 418 
 The time at which the outcomes were measured, sources of the cell lines and 419 
statistical methods used for data analysis were not reported. 420 
• Not relevant studies:  421 
 Clinical trial studies;  422 
 Studies conducted on medicinal plants that are not growing in Ethiopia. 423 
 Activity was not conducted for human pathogens (animal and plant pathogens).  424 
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3.3.Included studies 425 
 426 
3.3.1. In vivo anti-inflammatory studies 427 
 428 
Characteristics of the studies 429 
 430 
Thirty-one studies met the review criteria, and the year of publication of the studies ranged 431 
from 1994 to 2019. Thirty were peer-reviewed full articles, and one was an MSc thesis. All 432 
study designs met the criteria for inclusion and followed internationally accepted guidelines. 433 
Studies were conducted in eight different countries. These were Ethiopia (n=13), Austria (n=1), 434 
Costa Rica (n=1), Egypt (n=3), India (n=5), Iran (n=1), Nigeria (n=4) and Tunisia (n=2). 435 
Thirty-five (35) plant species were investigated for anti-inflammatory activity in animal models 436 
(Table 1). All the medicinal plants investigated were found in Ethiopia, and they were 437 
investigated for anti-inflammatory, analgesic, antioxidant, anti-microbial, wound healing, anti-438 
ulcer and/or anti-arthritic activities in animal models.   439 
The following plant families were reported in the studies of in vivo anti-inflammatory assays. 440 
These were Oleaceae, Lythraceae, Amaranthaceae, Meliaceae, Lamiaceae, Lauraceae, 441 
Asteraceae, Malvaceae, Myrtaceae, Apiaceae, Anunculaceae, Fabaceae, Zingiberaceae, 442 
Combretaceae, Acanthaceae, Polygonate, Salicaceae, Adianthaceae, Anacardiaceae, 443 
Rosaceae, Xanthorrhoeaceae, Cucurbitaceae and Moringaceae (Table 1). All the plants 444 
investigated were authenticated by botanists and had voucher numbers. The most studied plant 445 
parts were leaves (n=16), followed by aerial parts (8), roots (n=3), rhizomes (3), fruits (n=3), 446 
stem bark (n=2) and whole plants (n=2). The most frequently used techniques for the extraction 447 
of medicinal plant parts were maceration (n=20), followed by Soxhlet (n=6) and decoction 448 
(n=5) methods. The rest of the investigators used other methods and two combined methods 449 
(maceration and Soxhlet) together. Methanol (n=11) was the most frequently used solvent for 450 
crude extraction, followed by water (n=7), ethanol (n=6) and acetone (n=1).  451 
 Most studies used both sexes of Swiss albino mice (n=15) and Wistar rats (n=16). The age 452 
ranges of Swiss albino mice and Wistar rats used for the experiments were 6-8 weeks and 12 -453 
13 weeks, respectively.  454 
There was a wide range of variation in the concentration of plant extracts or fractions 455 
administered to the animals. Dose selection was made based on acute toxicity tests and pilot 456 
experiments. All concentrations used were safe doses to the laboratory animals and most 457 
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extracts were administered orally to the animals. On the other hand, (Naik et al., 2014), 458 
(Bhosale et al., 2012), (Mohammed et al., 2014), (Hosseinzadeh et al., 2011) and (Badilla et 459 
al., 1999) used intra-peritoneal and subcutaneous routes to administer the extracts to the 460 
animals, while (Khedir et al., 2016) used topical route of application (Supplementary table 1).  461 
Studies also used carrageenan-induced mouse paw oedema model to check the anti-462 
inflammatory activities of different extracts at three different doses,100, 200, and 400 mg/kg 463 
(Tadiwos et al., 2017; Abdissa, 2011; Wolde-Mariam et al., 2013; Ayal and Belay, 2019; Ching 464 
et al., 2009; Alemu et al., 2018). 465 
In another study, Hamad et al., (2019) and Gebremeskel et al., (2018) used 200, 400 and 600 466 
mg/kg doses for different plant extracts. However, Yonathan et al., (2006) used 400 mg/kg 467 
dose, Dilebo et al., (2011) used 300 and 500 mg/kg doses, Mulisa et al., (2015) used 250, 500 468 
and 750 mg/kg doses; 50, 150 and 350 mg/kg doses. Three studies, Adedapo et al., (2014), 469 
Masresha et al., (2012) and Mequanint et al., (2011) used 400, 600, and 800 mg/kg doses. 470 
However, Sewuye and Asres (2009) used a 200 mg/kg dose.  (Supplementary table 1).  471 
Similarly, cotton pellet-induced Granuloma method in mice was used to measure chronic 472 
inflammation. Umer et al., (2014) and Alemu et al., (2018) used 100, 200, and 400 mg/kg doses 473 
of 80% methanol extracts, However, Hosseinzadeh et al., (2011) used 5, 15, 30, 100, and 200 474 
mg/kg aqueous extract and 0.05, 0.15, and 0.35 g/kg ethanolic extracts for chronic 475 
inflammation. Vijayaraj and Kumaran (2018) and Sharma and Rajiani (2011) used 100 and 200 476 
mg/kg doses of ethanol and water extracts (Supplementary table 1).  477 
Aspirin, diclofenac, indomethacin and dexamethasone were used as standard drugs. The 478 
number of animal groups for anti-inflammatory activities depended on the number of different 479 
concentrations tested. The number of groups ranged from 3 to 5, where six animals were 480 
randomly assigned to each group.   481 
For the carrageenan-induced paw oedema method, the duration of exposure of the animals to 482 
the extracts (treatment) was 4-6hrs, and the time of measurement of end points was after 1, 2, 483 
3, 4, 5, and 6 hrs of exposure.  484 
At each end point the volume of paw oedema of the test and control groups was measured, and 485 
the percentage inhibition of oedema formation was calculated. For the cotton pellet-induced 486 
granuloma method (chronic inflammation), animals were exposed to treatment for 7 to 14 days 487 
and end points were measured on the 8th and 15th days; weight of cotton pellet (gm), granulation 488 
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tissue formation (gm) and percent inhibition of tissue granulation were the end points 489 
measured.  Seventeen studies used one-way analysis of variance (ANOVA) followed by 490 
Tukey’s post-hoc test, and six used the Student t-test.  491 
Most studies used carrageenan-induced paw oedema (n=23) to study the anti-inflammatory 492 
activity of the plant materials in laboratory animals, while some of them used other methods 493 
such as topical croton oil-induced or xylene-induced ear oedema method, histamine-induced 494 
paw oedema, and serotonin-induced paw oedema.   495 
Except for Dilebo et al., (2011), all studies showed at least one safe concentration of the plant 496 
material with significant inhibition of inflammation in animals in a dose-dependent manner. 497 
The maximum inhibition of oedema at low doses was reported by Tamrat et al., (2017) which 498 
showed 64.71%, 76.47% and 82.35% inhibition, respectively, at 50, 100, and 200 mg/kg of the 499 
methanol extract of J. abyssinicum 2h after carrageenan injection (Tadiwos et al., 2017).  500 
Aqueous extract of Achyranthes aspera exhibited higher inhibition of paw oedema formation 501 
at a dose of 800 mg/kg  compared with vehicle control in mice in 4h (Bhosale et al., 2012). 502 
Azadirachta indica chloroform extract was shown to have 53.25% inhibition of oedema in rats, 503 
comparable to the control drug indomethacin (46.9%) (Umar et al., 2014). Fraction-2 from 504 
Azadirachta indica showed higher inhibition of granuloma tissue formation at doses of 200 and 505 
400 mg/kg in rats. The activity of a flavonoid isolated from Lawsonia inermis was similarly 506 
reported by (Manivannan and Aeganathan, 2015) to have significant anti-inflammatory activity 507 
at doses of 100 and 200 mg/kg in rats after induction of inflammation in 3h.  508 
Acetone extract of Vernonia amygdalina (Gerawa) showed the fastest activity at low 509 
concentrations (Adedapo et al., 2014). They reported that 100 mg/kg and 200 mg/kg doses of 510 
the extract reduced inflammation after 1h, 2h and 3h incrementally compared to the controls. 511 
The 200 mg/kg dose of the extract gave the most pronounced inhibition of oedema after 3h, 512 
which was greater than that of the standard drug, indomethacin (Adedapo et al., 2014).  On the 513 
other hand, Dilebo et al., (2011) reported that the methanol extract of Ferula communis (Doge) 514 
was devoid of mouse paw oedema inhibition.  The highest dose of plant extract used was 515 
reported by Adeyem et al.(2002), which showed that the aqueous extract of Persea Americana 516 
(avocado) significantly (p<0.05) inhibited carrageenan-induced rat paw oedema at 1600 mg/kg,  517 
similar to that produced by 100 mg/kg of acetylsalicylic acid with percent inhibition of 57.2% 518 
and 58.0%, respectively (Adeyemi et al., 2002).  519 
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In another study, aqueous extracts of different parts of Citrullus colocynthis (roots, stems, fruits 520 
and seeds) injected intraperitoneally at a dose of 1 mg/kg and 4 mg/kg showed moderate to 521 
high activity (Marzouk et al., 2010).  In this study, immature fruits (88.33%) and seeds 522 
(98.06%) of Citrullus colocynthis showed better activity than ripe fruits (65.00% to 97.90%). 523 
The percent inhibition of aqueous extracts of the root and stem of Citrullus colocynthis was 524 
90.00% and 98.84%, respectively, showing better activity compared to the standard drug, 525 
acetyl salicylate of lysine (74.40% after 4h) (Marzouk et al., 2010).  526 
Three studies were included for the evaluation of chronic inflammation (cotton-pellet). The 527 
first study was reported by Alemu et al., (2018) who used 100, 200, and 400 mg/kg doses (oral) 528 
of Leonotis ocymifolia 80% methanol extract, and showed significant (p<0.001) inhibition of 529 
the formation of inflammatory exudates and granuloma mass. On the other hand, 28.91%, 530 
37.68%, and 45.91% inhibition of inflammatory exudate and 24.03%, 40.18%, and 50.65% 531 
reduction of granuloma were recorded at 100 mg/kg, 200 mg/kg, and 400 mg/kg doses, 532 
respectively, while, dexamethasone showed 52.89% and 79.54% inhibition of exudates and 533 
granuloma, respectively (Alemu et al., 2018).  534 
The second study used different concentrations of aqueous (0.005, 0.015, 0.03, 0.1, and 0.2 535 
g/kg) and ethanol (0.05, 0.15, and 0.35 g/kg) extracts of the aerial part of Myrtus communis 536 
(Hosseinzadeh et al., 2011). The aqueous extract exhibited significant inhibition of 537 
inflammation in a dose-dependent manner. Maximum efficacy (57.9%) was noted for a dose 538 
of 0.03 g/kg of the aqueous extract (Hosseinzadeh et al., 2011). The last study was on the anti-539 
inflammatory activity of ethanol and aqueous extracts of Caesalpinia pulcherrima (aerial) in a 540 
rat model. They used 100 mg/kg and 200 mg/kg doses of both ethanol and aqueous extracts 541 
orally. Both extracts showed a significant (p<0.05) inhibition of the growth of granuloma 542 
tissues compared to the controls. A water extract of 200 mg/kg dose (54.09±2.76%) produced 543 
significant (p<0.05) inhibition of granuloma tissue compared to indomethacin (53.32±9.00%). 544 
The aqueous extracts had better anti-inflammatory efficacy than the ethanol extracts (Sharma 545 
and Rajani, 2011).  546 
 Generally, the titles of the in vivo anti-inflammatory studies that were analysed were consistent 547 
with the objectives that the authors stated. Overall, the risk of performance and selection biases 548 
was low because studies adequately generated and applied the allocation sequence, and 549 
allocations were adequately concealed. Furthermore, the baseline characteristics of the 550 
different treatment groups did not significantly differ within any of the included studies. 551 
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However, eighteen studies did not report whether animals were randomly housed during the 552 
experiment (risk of performance bias) or not.  553 
In addition, not all studies reported whether the animal caregivers or investigators were blinded 554 
during the experiment (risk of performance bias). Similarly, it is unclear whether the outcomes 555 
were assessed blindly or not (detection bias). Five studies did not report whether all animals 556 
were included in the analysis (risk of attrition bias). Apparently, all studies followed the study 557 
protocol and were free of selective reporting outcomes.  558 
3.3.2. In vitro anti-inflammatory studies 559 
 560 
Characteristics of the studies 561 
 562 
For the in vitro anti-inflammatory activity, fifteen studies were included for full review and 563 
data extraction. The year of publication ranged from 2011 to 2019 and all of them were peer-564 
reviewed full articles. Like the in vivo anti-inflammatory studies, all the study designs met the 565 
inclusion criteria and followed internationally accepted guidelines/protocols. Studies were 566 
conducted in South Africa (n=1), USA (2), India (n=3), China (3), Canada (n=1), Tunisia (n=1), 567 
Morocco (n=1), Nigeria (n=1), Luxembourg (n=1), and Cameroon (n=1). However, no study 568 
was conducted in Ethiopia though the medicinal plants investigated can all be found in 569 
Ethiopia. The studies investigated the antioxidant, anti-granuloma and anti-bacterial activities, 570 
and anti-acetylcholinesterase activity.  571 
A total of 23 medicinal plant extracts were investigated (Table 1).  Two of the medicinal plants, 572 
commonly used in Chinese traditional medicine (Zingiber officinale and Artemisia annua), are 573 
also known for their medicinal use in Ethiopia. Plant parts such as leaves (n=7), seeds (n=5), 574 
whole plants (n=3), roots (n=2), bark, stems (n=1), fruits (n= 1), flowers (n=1) and bulbs (n=1) 575 
were investigated in these studies.  576 
Plant families of the plants reported in this review were Apocynaceae, Myrtaceae, 577 
Berberidaceae, Zingiberaceae, Apiaceae, Betulaceae, Meliaceae, Amaranthaceae, 578 
Brassicaceae, Cucurbitaceae, Rosaceae, Anacardiaceae, Lythraceae, Lamiaceae, Myrtaceae, 579 
Solanaceae, Fabaceae, Poaceae, Verbenaceae, Rutaceae, Liliaceae, Euphorbiaceae and 580 
Capparidaceae (Table 1).  581 
For the in vitro anti-inflammatory assays, commercially available cell lines and mononuclear 582 
cells (macrophages) isolated from laboratory animals were used. These were; Primary human 583 
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neonatal fibroblasts (HDF3CGF assays/ELSEA), RAW264.7 cells lines (for nitric oxide 584 
assay), RAW 264.7 cell lines  (cytokines assay, Real time PCR and Western blotting), 585 
peritoneal mice macrophages (cytokines assay, western blotting), HP-1 cells lines (TNF-alpha 586 
assay), Murine macrophages RAW264.7 cells, mouse splenocytes, and human embryonic 587 
kidney 293 (HEK293) cell lines,  primary human neonatal fibroblasts (gene expression assay) 588 
and kits for colorimetric in vitro anti-inflammatory assay were used.  589 
 590 
Cytotoxicity assays were conducted for all plant extracts tested in the in vitro models and all 591 
concentrations used were safe to the cell lines used in the experiments. The concentration of 592 
essential oils used for in vitro anti-inflammatory activity ranged from 0.00041- 0.011% (v/v).   593 
Han and Parker, (2017) tested 0.011, 0.0037, 0.0012, and 0.00041% (v/v) of the essential oil 594 
of Eugenia caryophyllata, and noted that they significantly decreased the levels of 595 
inflammatory biomarkers such as vascular cell adhesion molecule-1 (VCAM-1), interferon 596 
gamma-induced protein 10 (IP-10), interferon-inducible T-cell a chemoattractant (I-TAC), and 597 
monokine induced by c interferon (MIG). This indicated that Eugenia caryophyllata essential 598 
oil may possess anti-inflammatory and pro-wound-healing properties. The effects of Eugenia 599 
caryophyllata essential oil on these biomarkers were concentration-dependent (Han and 600 
Parker, 2017a) (Supplementary table 1).  601 
Methanol extracts of Lawsonia inermis showed cyclo-oxygenase enzyme inhibition (IC50 value 602 
of 51 ± 0.23 mg/L), and inhibition of heat induced albumin denaturation and hemolysis (IC50 603 
= 170.24 μg/ml) (Chaibi et al., 2017; Bouhlali et al., 2016).  Similarly, Rosa damascena flower 604 
extract exhibited the highest inhibition of haemolysis (IC50 = 125.02 µg/ml). Fraction-2 (F-2) 605 
of chloroform extract of Azadirachta indica inhibited the production of IL-1 and TNF-ά in a 606 
dose dependent manner. Fractions 1, 2 and 3 had significant activity on COX-1 and COX-2 at 607 
200 µg/ml, comparable to indomethacin.  608 
In another study, 0.01% (v/v) essential oil of Cuminum cyminum inhibited iNOS and COX-2 609 
mRNA levels in Lipopolysaccharide (LPS)-stimulated cells; and reduction of proinflammatory 610 
cytokines was observed in a dose-dependent manner. Cuminum cyminum essential oil (0.01%) 611 
reduced IL-1β and IL-6 mRNA expressions to 30.2% and 1.3% in  LPS-stimulated cells (Wei 612 
et al., 2015). Furthermore, 0.01% Cuminum cyminum essential oil produced 52% inhibition of 613 
nuclear NF-kB p65 levels in LPS-stimulated cells, which exhibited anti-inflammatory effects 614 
partially by blocking NF-kB activation; it also resulted in 45% and 53% inhibition of LPS-615 
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induced JNK and ERK phosphorylation which was partially attributed to regulating JNK and 616 
ERK pathways (Wei et al., 2015) (Supplementary table 1).  617 
Essential oils of Allium sativum, Allium cepa, Drypetes gossweileri, Pentadiplandra brazzeana 618 
were also tested and inhibited the denaturation of protein (albumin) in a concentration 619 
dependent manner (3.125 to 125 µg/ml) (Ndoye Foe et al., 2016). In addition, essential oil of 620 
Cymbopogon flexuosus (lemon grass) significantly decreased production of several 621 
inflammatory biomarkers, including vascular cell adhesion molecule 1 (VCAM-1), interferon 622 
gamma-induced protein 10 (IP-10), interferon-inducible T-cell alpha chemoattractant (I-TAC), 623 
and monokine induced by gamma interferon (MIG) (Han and Parker, 2017)  (Supplementary 624 
table 1).  625 
The time of measuring the outcomes for the essential oils varied significantly across the 626 
experiments, i.e., 24h (n=4), 15 minutes (n=1) 10 minutes (n=1) and 30 minutes (n=1).  627 
The concentration of plant extracts reported ranged from 0.25 µg/ml to 100 µg/ml. The 628 
minimum concentration reported for in vitro anti-inflammatory activity was 0.25 µg/ml for 629 
dichloromethane and ethanol extracts of Huernia hystrix. In this study, petroleum ether extract 630 
of roots, all the petroleum ether and dichloromethane extracts showed good activity by 631 
inhibiting cyclo-oxygenase enzyme 1 and 2 (COX-1 and COX-2) by more than 70% (Amoo et 632 
al., 2012).  The highest concentration of methanol extract of Alnus nepalensis, used for the test 633 
was 100 µg/ml  (Saxena et al., 2018). The in vitro anti-inflammatory activity of the leaf extract 634 
of Alnus nepalensis against pro-inflammatory cytokines (TNF-α and IL-6) were assessed using 635 
ELISA technique in LPS-induced inflammation macrophage cells at concentrations of 10, 30 636 
and 100 µg/ml. Alnus nepalensis butanol fraction significantly inhibited the production of pro-637 
inflammatory cytokines (TNF- α and IL-6) in a dose-dependent manner (Saxena et al., 2018).  638 
In another study, anti-inflammatory activity of twelve different medicinal plants was 639 
investigated.  Amaranthus dubius was reported to be the most potent extract with IC50 of 9 640 
𝜇𝜇g/ml, followed by Ocimum americanum, Vigna unguiculata, and Zanthoxylum chalybeum 641 
with IC50 values of 16, 27, and 47 𝜇𝜇g/ml respectively. However, Brassica oleracea, Ocimum 642 
gratissimum, Azadirachta indica and Mangifera indica showed weaker dose responses (Tufts 643 
et al., 2015).  644 
Generally, all in vitro anti-inflammatory studies included fulfilled the test definition, which 645 
included the purpose, requirements and scientific basis of the tests.  In addition, all the methods 646 
followed were valid, internationally acceptable, clearly written and documented in vitro 647 
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method descriptions.  Relevant documentation of proof of sterility, laboratory consumables 648 
suitability and acceptability for use was reported in all studies. However, none of the studies 649 
reported evidence of provision of relevant and adequate education and training for all personnel 650 
to maintain high quality work and safety.  651 
Furthermore, no studies reported whether the in vitro cell and tissue culture facilities were fit 652 
for purpose, or a detailed understanding of the workflow for the in vitro methods, which may 653 
adversely affect the quality of the work performed. One study reported the compliance of 654 
laboratory suppliers with good laboratory practice (GLP) principles, whereas nine of them did 655 
not report this. Reference data to assess the relevance of in vitro methods were provided; 656 
sources, components and batch numbers of media and serum used were precisely specified; 657 
and maximum acceptable levels of serum components were defined well.  658 
In addition, reference and control items, concentration of solvent(s) used, suitability of 659 
reference and control items, and justification for the selection of the reference item(s) were 660 
reported in all the studies. However, eight studies did not report the applicability domains of 661 
the in vitro methods, and the limitations of the test methods were not described well (risk of 662 
performance bias).  663 
The number of replicates for each testing condition, the concentration level(s) used for the test 664 
and control items and the measurement of the outcomes were uniform across the whole plate 665 
(well-to-well), between plates and across multiple runs which minimised any potential 666 
systematic effects. Appropriate statistical methods were used for all in vitro anti-inflammatory 667 
studies.  668 
Table 1. Summary of common medicinal plants investigated as anti-inflammatory agents from 669 
literature search  670 











Oleaceae Herb R 1 (Tadiwos et al., 2017) 
2 Leonotisocymifolia Lamiaceae  Shrub L 1 (Alemu et al., 2018) 
3 Persea americana Lauraceae Tree L 1 (Adeyemi et al., 2002) 
4 Bidens Pilosa  Asteraceae, Herb L 1 (Dilebo et al., 2011) 
5 Malva verticillate Malvaceae, Herb L 1 (Dilebo et al., 2011) 
6 Syzygium guineens Myrtaceae, Tree L 1 (Dilebo et al., 2011) 
7 Ferula communis  Apiaceae, Herb Rh 1 (Dilebo et al., 2011) 
8 Ranunculus multifidus  Ranunculaceae    Herb Ae 1 (Dilebo et al., 2011) 
9 Stereospermum 
kunthianum 
Bignoniaceae Shrub Sb 1 (Ching et al., 2009) 
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10 Melilotus elegans Fabaceae Herb L 1 (Asres et al., 2005) 
11 Urera baccifera Urticaceae Shrub L 1 (Badilla et al., 1999) 
12 Curcuma longa  Zingiberaceae Herb Rh 1 (Mohamed et al., 2013) 
13 Cinnamomum 
xylanicum 
Lauraceae Herb B 1 (Mohamed et al., 2013) 
14 Thyme vulgaris  Lamiaceae Herb Ae 1 (Mohamed et al., 2013) 
15 Combretum 
aculeatum 
Combretaceae Tree Ae 1 (Hamad et al., 2019) 
16 Myrtus communis Myrtaceae Shrub Ae 1 (Hosseinzadeh et al., 
2011) 
17 Vernonia amygdalina Asteraceae Shrub L 1 (Adedapo et al., 2014) 
18 Aniso testrisulcus Acanthaceae Herb Ae 1 (El-Shanawany et al., 
2014) 
19 Calpurnia aurea Fabaceae Shrub L 1 (Ayal and Belay, 2019) 
20 Caesalpinia 
pulcherrima 
Fabaceae Shrub Ae 1 (Sharma and Rajani, 
2011) 
21 Diclipter alaxata Acanthaceae Herb Ae 1 (Wolde-Mariam et al., 
2013) 
22 Rumex abyssinicus Polygonaceae Herb Rh 1 (Mulisa et al., 2015) 
23 Dovyalis abyssinica Salicaceae Shrub F 1 (Abdissa, 2011) 
24 Ocimum lamiifolium Lamiaceae Herb L 1 (Mequanint et al., 
2011) 
25 Cheilanthes farinosa Adianthaceae Shrub Ae 1 (Yonathan et al., 2006) 
26 Pistacia lentiscus Anacardiaceae Shrub F 1 (Khedir et al., 2016) 
27 Ocimum suave Labiatae Herb L 1 (Masresha et al., 2012) 
28 Rosa abyssinica Rosaceae, Shrub R 1 (Sewuye and Asres, 
2009) 
29 Salvia nilotica  Lamiaceae Shrub L 1 (Sewuye and Asres, 
2009) 
30 Aloe megalacantha Xanthorrhoeace
ae 
Shrub L 1 (Gebremeskel et al., 
2018) 
31 Citrullus colocynthis Cucurbitaceae Herb R, S, 
F 
1 (Marzouk et al., 2010) 
32 Moringa stenopetala Moringaceae Tree L 1 (Tamrat et al., 2017) 
33 Lawsonia inermis Lythraceae Tree L 6 (Annavarapu et al., 
2016; Bouhlali et al., 
2016; Vijayaraj and 
Kumaran, 2018; Chaibi 
et al, 2017) 
34 Azadirachta indica  Meliaceae Tree L 3 (Annavarapu et al., 
2016, Nik et al., 2014, 
Pereira et al., 2012, 
Schumacher et al., 
2011, Tftus et al., 2015, 
Umar et al., 2014) 
35 Achyranthes aspera Amaranthaceae Herb  L 2 (Bhosale et al., 2012; 
Gokhale et al., 2002) 
36 Huernia hystrix Apocynaceae Herb S, R, 
W 
1 (Amoo et al., 2012) 
37 Eugenia 
caryophyllata 
Myrtaceae Tree S 1 (Han and Parker, 
2017a) 
38 Zingiber officinale 
Rosc 
Zingiberaceae, Herb W 1 (Chen and Zhang, 
2014) 
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39 Artemisia annua Asteraceae,  Herb W 1 (Chen and Zhang, 
2014) 
40 Cuminum cyminum  Apiaceae Herb S 3 (Bouhlali et al., 2016; 
Tomy et al., 2014; Wei 
et al., 2015) 
41 Alnus nepalensis Betulaceae Tree L 1 (Saxena et al., 2018) 
42 Amaranthus dubius Amaranthaceae Herb L 1 (Tufts et al., 2015) 
43 Brassica oleracea Brassicaceae Herb L 1 (Tufts et al., 2015) 
44 Cucurbita maxima Cucurbitaceae Herb L 1 (Tufts et al., 2015) 
45 Eriobotrya japonica Rosaceae Shrub F 1 (Tufts et al., 2015) 
46 Mangifera indica Anacardiaceae Tree L 1 (Tufts et al., 2015) 
47 Ocimum americanum Lamiaceae Herb F 1 (Tufts et al., 2015) 
48 Ocimum gratissimum  Lamiaceae Herb F 1 (Tufts et al., 2015) 
49 Psidium guajava Myrtaceae Shrub L 1 (Tufts et al., 2015) 
50 Solanum scabrum Solanaceae Herb F 1 (Tufts et al., 2015) 
51 Vigna unguiculata Fabaceae Herb L 1 (Tufts et al., 2015) 
52 Vitex payos Verbenaceae Tree F 1 (Tufts et al., 2015) 
53 Zanthoxylum 
chalybeum 
Rutaceae Tree L 1 (Tufts et al., 2015) 
54 Allium sativum L Liliaceae Herb Bu 1 (Ndoye Foe et al., 
2016) 
55 Allium cepa L Liliaceae Herb Bu 1 (Ndoye Foe et al., 
2016) 








Poaceae Herb W 1 (Han and Parker, 
2017b) 
59 Rosa damascena Rosaceae, Shrub Fl  (Bouhlali et al., 2016) 
Leaves = L, root = R, Stem Bark =SB, Fruits =F, Bark =B, Aerial = Ae, Flower = Fl, Stem =St, Rhizo 671 
= Rh, Bulbs = Bu, Seed = S, Berries = Be, Whole =W 672 
 673 
3.3.3. In vivo wound healing studies 674 
 675 
Characteristics of the studies 676 
 677 
Fifteen in vivo wound healing studies were eligible for data extraction and the year of 678 
publication ranged from 2001 to 2019. Except for one study that investigated both anti-679 
inflammatory and wound healing activities, all studies investigated wound healing as a health 680 
outcome category. All studies included were peer-reviewed full research articles, and were 681 
conducted in four countries: Ethiopia (n=9), India (n=5), Pakistan (n=1) and Cameroon (n=1).  682 
In this model, 14 medicinal plant species, namely Commiphora guidottii chiov, Achyranthes 683 
aspera, Rumex abyssinicus, Calpurnia aurea, Croton macrostachyus, Kalanchoe petitiana, 684 
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Aloe megalacantha, Stereospermum kunthianum, Hibiscus micranthus, Lantana camara, 685 
Clematis longicauda, Clematis burgensis, Lawsonia inermis and Azadirachta indica, 686 
belonging to 12 families, were investigated (Table 2). 687 
All studied medicinal plant parts had voucher numbers and were authenticated by a botanist. 688 
The most studied plants parts were leaves (n=9) and the rest were stem bark (n=2), rhizome 689 
(n=1), leaf latex (n=1) and one plant constituent, oleo-gum-resin. Eleven studies used excision 690 
and incision wound models to investigate wound contraction and the period of epithelization 691 
and wound tensile strength, respectively, while three of them used only excision wound 692 
models. Swiss albino rats and Swiss albino mice of both sexes were used for both incision and 693 
excision models.  694 
The age range of mice used for the studies was 6 – 11 weeks and 12 – 35 weeks for rats. All 695 
studies reported positive and negative controls: they used 0.2 % (w/v) nitrofurazone ointment 696 
and 1% silver sulfadiazine cream as positive control and simple ointment BP as negative 697 
control. Ten studies used one-way analysis of variance (ANOVA) followed by Dunnett’s test 698 
for experimental data analysis, and one study used the Student t-test. All studies considered a 699 
95% confidence interval and p < 0.05 value as statistically significant.  700 
Except for the studies conducted by Hawaze et al., (2013), Mekonnen et al., (2013) and 701 
Begashaw et al., (2017), all studies prepared plant extracts and essential oils in a simple 702 
ointment base according to the British Pharmacopoeia (BP) using hard paraffin, cetostearyl 703 
alcohol, white soft paraffin and wool fat. Then, plant materials were incorporated into the 704 
simple ointment to make plant extract/essential oil-ointments of uniform consistency and 705 
smooth texture.  706 
All investigated medicinal materials showed significant (p<0.05) wound contraction at a 707 
concentration range of 5% - 10% (w/w) and reduced the period of epithelialization relative to 708 
the negative controls. Gebrehiwot et al. (2015) reported that 4% essential oil and 5% resin from 709 
Commiphor aguidottii Chiov in ointment base, applied topically on a daily basis to incision and 710 
excision wounds assisted wound contraction significantly (p< 0.05) from day 8 to16 as 711 
compared to the negative controls. In this study, resin showed a significant (p < 0.05) difference 712 
in tensile strength compared to the simple ointment-treated groups.  713 
In another study, reported by Fikru et al., (2012), 2.5%, 5% and 10% (w/w) 80% methanol 714 
extracts of Achyranthes aspera increased the percentage of wound contraction starting from 715 
day 9, and complete wound healing was seen in rats treated for 21 days. Epithelization time 716 
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was also shortened for animals treated with 2.5%, 5% and 10% (w/w) methanol extracts. On 717 
the 21st day after treatment, the 5% and 10% plant extract-treated group showed a relatively 718 
well-organized epidermal layer, increased number of mature fibroblasts (fibrocytes) cells and 719 
high levels of neovascularization and epithelization. The total DNA content in wound tissue 720 
samples of animals treated with 2.5%, 5% and 10% (w/w) plant extracts were  shown 721 
significantly (p<0.05) higher than the amount detected in the negative control groups (Fikru et 722 
al., 2012).  723 
Rat incision wounds treated with ethanol extract of Lawsonia inermis demonstrated a 724 
significant increase in skin breaking strength, an increase in the level of hydroxyproline 725 
content, and greater aggregation of macrophages with fewer fibroblasts and collagen fibres 726 
(Shivananda et al., 2008). In a similar study, commercially formulated Lawsonia inermis 727 
demonstrated faster reduction in scar tissue compared to non-treated animals (Khaliq et al., 728 
2018).  729 
In a study by Maan et al., (2017), rates treated with 15% (w/w) aqueous extract of Azadirachta 730 
indica showed significant wound contraction after the 10th day, and higher hydroxyproline 731 
content was exhibited by aqueous, aqueous-ethanol (1:1) and ethanol extracts when compared 732 
to vehicle-treated animals. Aqueous, aqueous-ethanol (1:1) and ethanol extracts showed higher 733 
skin breaking strength, and complete epithelization was observed after the 14th day of 734 
treatment, comparable to the reference drug. Similarly, topical application of 5% w/w ointment 735 
of Azadirachta indica significantly increased the percentage of wound contraction and 736 
decreased epithelization time. In addition, the mean scar area was significantly decreased, 737 
increased fibro-collagenous tissue deposition, and increased (p<0.01) tensile strength of the 738 
test groups compared to the control groups, which was comparable to the standard drug. 739 
Mulisa et al., (2015) studied the methanol extract (5% and 10% (w/w) in ointment base) of 740 
Rumex abyssinicus, showing a significantly increased wound contraction rate in mice 741 
compared to control. Time to epithelization was shorter by 23.1% for 10% (p<0.001), 22.1% 742 
for nitrofurazone (p<0.001) and 16.3% for 5% (p<0.05) compared to those treated with the 743 
ointment base. The percentage of hydroxyproline content increased by 102.2% with 744 
nitrofurazone (p < 0.001) followed by 74% with 10% extract (p < 0.001) and 31.6% with 5% 745 
extract (p < 0.05). The tensile strength was significantly increased by approximately 36.2% (p 746 
< 0.05), 57.2% (p < 0.001), and 79.1% (p < 0.001) with 5% and 10% of the extract and 747 
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nitrofurazone ointments, respectively, compared to controls treated with the ointment base 748 
(Mulisa et al., 2015).   749 
Similarly, Ayal and Belay (2019) evaluated methanol extract, chloroform, ethyl acetate and 750 
aqueous fractions of Calpurnia aurea at two concentrations (5% and 10%) in mice. They 751 
reported that 10% (w/w) crude extract ointment showed significant (p<0.05) wound contraction 752 
on day two post-wounding, comparable with the activity of nitrofurazone 0.2% ointment in 753 
mice. Starting from day 4, the 10% w/w crude extract ointment revealed a higher percentage 754 
of wound contraction than the standard. The percentage of wound contraction of 10% w/w 755 
ointment of the aqueous fraction was also significantly (p<0.001) higher on most post-756 
wounding days, except on day 16 (p<0.01) compared to the negative control. The periods of 757 
epithelialization of mice treated with the 5% w/w and 10% w/w aqueous fractions and the 758 
standard ointments were significant (p<0.01) compared to the negative control. The mice 759 
treated with 10% w/w crude extract ointment had the highest percentage of tensile strength. 760 
In another study by Fikru et al., (2012), the 80% methanol extract (5% and 10% in ointment 761 
base) of Croton macrostachyus showed a significant (p < 0.05) difference on the 6th day after 762 
treatment when compared with the simple ointment-treated group in rats. Likewise, the test 763 
groups needed a significantly shorter epithelization time. The 10th day photographs showed 764 
that the group treated with 10% (w/w) extract of Croton macrostachyus ointment demonstrated 765 
relatively better healing, with skin colour close to normal, and a smooth surface. Rats treated 766 
with 5 and 10% (w/w) ointments of the extracts showed higher breaking strengths (Mechesso 767 
et al., 2016).  768 
Leaf latex of Aloe megalacantha (5% and 10 % in ointment base) were shown to have more 769 
rapid wound closure than standard drugs in albino-Wistar rats.  The maximum rate of wound 770 
contraction was observed on the 11th (94.4%), 13th (100%), and 15th (100%) days after wound 771 
creation. The rate of wound closure was comparable with the 11th (88.58%), 13th (99.42%), and 772 
15th (100%) treatment days when 0.2% nitrofurazone was used. The 5% (w/w) latex showed 773 
slightly more rapid epithelialization than either 10% (w/w) latex or reference drug-treated 774 
animals (Gebremeskel et al., 2018).  775 
Mekonnen et al., (2013) studied 80% methanol extract, chloroform, methanol and distilled 776 
water fractions of Kalanchoe petitiana in ointment bases and extracts and fractions alone in an 777 
excision and incision mouse wound model.  Topical application of both 5% and 10% of the 778 
crude hydroalcoholic extract ointments to the excision wound model significantly increased (p 779 
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< 0.01) wound contraction rates and shortened the epithelization time compared to the control 780 
animals. The 5% ointment showed a slightly higher rate of wound contraction and shorter 781 
epithelization period than the higher dose (10% ointment). The chloroform fraction was devoid 782 
of any wound healing activity. The epithelization period was significantly shorter in animals 783 
treated with 5% and 10% concentrations of methanol and aqueous fractions (p < 0.05 in all 784 
cases) compared to controls. The hydroalcoholic crude extract showed greater wound healing 785 
effects than the three fractions, as evidenced by faster wound contraction rate and shorter 786 
epithelization period (Mekonnen et al., 2013) (Supplementary table 2). 787 
The remaining three studies, namely Begashaw et al., (2017), Dash et al., (2017) and Hawaze 788 
et al., (2013) showed that methanol and aqueous extracts of Hibiscus micranthus, Lantana 789 
camara, Clematis longicauda, and Clematis burgensis exhibited significantly faster wound 790 
contraction, faster tissue epithelization, and significantly increased tensile strength of tissues 791 
in excision and incision wounds of rats (Supplementary table 2). 792 
All the in vivo wound healing studies generated and applied an allocation sequence adequately. 793 
The distribution of relevant baseline characteristics was similar for the intervention and control 794 
groups. The timing of disease induction was adequate as per the protocol, and the allocation of 795 
laboratory animals to the different groups was properly concealed. However, six studies did 796 
not report whether they placed the cages or animals randomly within the animal room or facility 797 
(risk of performance bias). Five authors did not report the age category, and three authors did 798 
not report the sources of the laboratory animals. Two authors did not report the housing 799 
conditions of laboratory animals before or during the experiment, or the sources of diet for the 800 
animals. In addition, it was not clear whether the caregivers or investigators were blinded from 801 
knowing which intervention each animal received during the experiment, or whether the 802 
animals were selected at random or all animals were included in outcome assessment (risk of 803 
detection bias).  804 
All studies reported that they used a study protocol that was available, and all the study’s pre-805 
specified primary and secondary outcomes were reported in the current manuscript. They used 806 
proper statistical analysis methods that were free of unit of analysis errors and free of design-807 
specific risks of biases.  808 
3.3.4. In vitro wound healing 809 
 810 
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Characteristics of the studies 811 
 812 
Two in vitro wound healing studies were included. These were conducted in Ethiopia and 813 
Denmark. Both were peer-reviewed full articles, met the inclusion criteria, and were conducted 814 
according to internationally acceptable guidelines/protocols. The assay methods used for these 815 
in vitro tests were wound healing scratch assays, and antioxidant and radical scavenging 816 
activity assays, which were correlated with wound healing activity.  817 
A total of eighteen Ethiopian medicinal plants were studied in the included two studies: 818 
Aframomum melegueta, Allophylus spicatus, Annona senegalensis Pers, Folium Cissusqua 819 
drangularis, Herba Gymnanthemum coloratum, Folium cum Flos Radix, Jasminum 820 
dichotomum, Folium Leonotis nepetifolia, Melanthera scandens, Herba Millettia thonningii, 821 
Ocimum gratissimum L., Philenoptera cyanescens, Fructus Rourea coccinea, Folium Radix 822 
Thonningia, Herba Trichilia monadelpha, Triumfetta rhomboidei, Uvaria ovata and Aloe 823 
Harlan (Table 2). These belong to 14 plant families. All the plants were authenticated by a 824 
botanist and had voucher numbers (Table 2).  825 
Stamen, radix, aerial parts, leaves, cortex, leaf latex, stems and flowers bulbs were parts of the 826 
plants included in these in vitro studies; and leaf latex of aloe, aqueous, methanol, 70% ethanol, 827 
petroleum ether, ethyl acetate and methanol extracts were the types of plant extracts used in 828 
these studies.  829 
Seventeen medicinal plants were evaluated at a concentration of 10 𝜇𝜇g/ml for the in vitro 830 
wound healing. Only five of the 17 plant species tested increased proliferation or migration of 831 
fibroblasts in the scratch assay. These were Allophylus spicatus (warm and cold extracts of 832 
herbals), Philenoptera cyanescens (warm extract), Melanthera scandens (warm extract), 833 
Ocimum gratissimum (cold extract), and Jasminum dichotomum (warm extract). The warm 834 
water extract of folium/fructus of Philenoptera cyanescens was shown to have a 100% 835 
proliferation/migration rate compared to the negative control group (Freiesleben et al., 2017) 836 
(Supplementary table 2).  837 
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In the second study, the antioxidant activities of the latex and isolated compounds of Aloe 838 
harlana Reynolds were tested using two complementary test systems, namely DPPH and 2‐839 
deoxyribose degradation assay methods. It was shown that increasing concentrations (1000, 840 
500, 250 and 125 µg/ml) of the latex and isolated compounds increased the percent radical 841 
scavenging rates (Figure 2). The IC50 of the latex was found to be 14.21 µg/ml, while that of 842 
ascorbic acid (used as a reference) was 4.76 µg/ml. Both the isolated compounds and latex 843 
exhibited free radical scavenging properties in a concentration-dependent manner. Similarly, a 844 
compound, 7‐O‐Methylaloeresin A, was shown to have much stronger radical scavenging 845 
activity (IC50 = 0.021 mM) than aloin. At a concentration of 1.81 mM, 7‐O‐methylaloeresin A 846 
was shown to have a maximum inhibitory effect of 63.4%, which was comparable to the 847 
reference material, butylhydroxytoluene (BHT) (70.7%). Aloin was shown to have less activity 848 
(IC50 = 0.600 mM) in the deoxyribose degradation assay (Asamenew et al., 2011) 849 
(Supplementary table 2).  850 
 851 
Both in vitro studies fulfilled the test definition criteria, the purpose and scientific basis of the 852 
tests. In addition, valid and international acceptable in vitro method(s), written and documented 853 
in vitro method description and related standard operating procedure(s) were followed. 854 
However, neither study reported evidence of provision of adequate education and training for 855 
personnel to promote high quality work and safety. In addition, there was no evidence of 856 
minimisation of the risk of errors (e.g., mix-ups) or avoidance of cross-contamination which 857 
might adversely affect the quality of the work performed, or safety measures to avoid 858 
environmental and individual contamination. Furthermore, there was no report of equipment 859 
calibration, or compliance of laboratory suppliers with GLP principles of international 860 
standards which are recommended for formal quality systems.  861 
7‐O‐Methylaloeresin A Aloin 
Figure 2: Structures of aloin and 7‐O‐methylaloeresin A. 
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Evidence showed that the cell lines were free from any contaminants, and that identity, 862 
functionality and genetic stability, batch number and sources of antioxidant test kits, media and 863 
cell lines were reported in both studies. Reference and control items were described well.  864 
However, no justification was provided for the selection of the reference item(s) or the 865 
applicability domains of the in vitro method, and limitations of the in vitro test were not well 866 
described. In addition, compatibility and toxicity of the solvent was not reported in either study.  867 
Concentration levels of plant extracts and controls, number of replicas of experiments, 868 
evidence of uniform fashion treatment, cell seeding and reagents across the whole plate (well-869 
to-well) were reported in both studies to minimise systematic errors.  870 
Table 2: Summary of common medicinal plants identified from literature search for wound 871 
healing 872 













1 (Gebrehiwot et al., 
2015) 
2 Achyranthes aspera Amarenthaceae Herb L 1 (Fikru et al., 2012) 
3 Rumex abyssinicus Polygonaceae Herb Rh 1 (Mulisa et al., 2015) 




Euphorbiaceae Tree L 1 (Mechesso et al., 
2016) 
6 Kalanchoe petitiana Crassulaceae Herb L 1 (Mekonnen et al., 
2013) 
7 Aloe megalacantha Xanthorrhoeac
eae 




Bignonias Herb Sb 1 (Tsala, 2016) 
9 Hibiscus 
micranthus 
Malvaceae Herb L 1 (Begashaw et al., 
2017) 
10 Lantana camara  Verbenas Herb L 1 (Dash et al., 2001) 
11 Clematis 
longicauda 
Ranunculaceae Shrub L 1 (Hawaze et al., 2013) 
12 Clematis burgensis Ranunculaceae Shrub L 1 (Hawaze et al., 2013) 
13 Lawsonia Inermis Lythraceae Tree L 2 (Khaliq et al., 2018; 
Nayak BS, Isito G, 
Davis EM, 2008) 
14 Azadirachta Indica Meliaceae Tree L 2 (Maan et al., 2017; 
Nagesh et al., 2015) 
15 Aframomumme 
legueta 
Zingiberaceae Herb S 1 (Freiesleben et al., 
2017) 




Annonaceae Shrub L 1 (Freiesleben et al., 
2017) 













Fabaceae Shrub L 1 (Freiesleben et al., 
2017) 




Lamiaceae , Herb Ae 1 (Freiesleben et al., 
2017) 






















Meliaceae Shrub R 1 (Freiesleben et al., 
2017) 
29 Uvaria ovata Annonaceae Shrub B, R 1 (Freiesleben et al., 
2017) 
30 Aloe harlana Aloaceae Shrub L 1 (Asamenew et al., 
2011) 
Leaves = L, root = R, Stem Bark =SB, Fruits =F, Bark =B, Aerial = Ae, Flower = Fl, Stem =St, 873 
Rhizo46me = Rh, Bulbs = Bu, Seed = S, Berries = Be, Whole =W 874 
 875 
4. Discussion 876 
 877 
The purpose of this review was to demonstrate the anti-inflammatory and wound healing 878 
activities of Ethiopian medicinal plants that might potentially be used for limb care 879 
(particularly, tropical lymphoedema and associated wounds).  This systematic review identified 880 
a total of 63 articles covering four different experimental models. Of these, 31 used in vivo 881 
anti-inflammatory, 15 in vitro anti-inflammatory, 15 in vivo wound healing, and 2 in vitro 882 
wound healing models. Overall, medicinal plant extracts tested for these two conditions in in 883 
vitro and in vivo models were shown to have good activity. Despite the heterogeneity of the 884 
studies, all plant extracts investigated succeeded in reducing experimentally-induced 885 
inflammation in animals, in down-regulation of inflammatory and pro-inflammatory cells, and 886 
in promotion of wound healing.  887 
  888 
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In in vivo anti-inflammatory assays, 80% methanol root extract of Jasminum abyssinicum was 889 
shown to have good activity in a dose-dependent manner, possibly through secondary 890 
metabolites such as saponins, terpenoids, triterpenes, glycosides and flavonoids (Tadiwos et 891 
al., 2017). The anti-inflammatory activity might also be attributed to polyphenols like 892 
flavonoids, which are present in the extracts and exert their activity through free radical 893 
scavenging and inhibition of inflammatory pathways (Kaushik et al., 2012). This agrees with 894 
reports that flavonoids inhibited the biosynthesis of prostaglandins by inhibiting COX and 895 
LOX  inflammatory pathways (Adebayo et al., 2015; Amoo et al., 2012).  896 
Acetone extract of Vernonia amygdalina (Gerawa) was also shown to have fast activity at low 897 
concentrations due to its inhibitory effect on the biosynthesis of prostaglandin E2 (PGE2) and 898 
prostaglandin D2 (PGD2). It contains secondary metabolites such as tannins, potent 899 
cyclooxygenase inhibitors (Adedapo et al., 2014). Tannins also act on leukocyte migration and 900 
antagonism of the phlogistic actions of mediators of inflammation  (M.L.R. Mota, G. Thomas, 901 
1985). This report is in agreement with the findings of Mulisa and colleagues (Mulisa et al., 902 
2015).  903 
In another study, aqueous extracts of the root and stem of Citrullus colocynthis were shown to 904 
have good activity compared to aspirin. This activity is due to the presence of secondary 905 
metabolites (alkaloids), which have analgesic and anti-inflammatory activities and act via 906 
inhibition of pro-inflammatory cytokines (IL-6 and IL-1) and the expression of COX-2, and 907 
increasing the level of anti-inflammatory cytokine IL-4 in carrageenan-injected rat paw tissues 908 
(Marzouk et al., 2010). A similar mechanism of action of alkaloids was reported by others 909 
(Bribi et al., 2015).  The anti-inflammatory and analgesic properties of alkaloids have also been 910 
reported by other authors (Barbosa-Filho1 et al., 2006; Chester et al., 2017). For instance, 911 
colchicine is an alkaloid used for the treatment of gout (arthritis) and leukocytoclastic vasculitis 912 
(Barbosa-Filho1 et al., 2006).   913 
The methanol extract of Leonotiso cymifolia (Alemu et al., 2018), aqueous extract of Myrtus 914 
communis (Hosseinzadeh et al., 2011), ethanol and aqueous extract of Caesalpinia pulcherrima 915 
(Sharma and Rajani, 2011) were evaluated for chronic inflammation and showed inhibition of 916 
formation of inflammatory exudates and granuloma mass in a dose-dependent manner 917 
compared to the standard drugs. Aqueous extract of Caesalpinia pulcherrima (200 mg/kg dose) 918 
showed better activity than indomethacin (Sharma and Rajani, 2011) because of its major 919 
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constituent, flavonoids, known to inhibit fibroblasts and the synthesis of collagen and 920 
mucopolysaccharides during granuloma tissue formation (Rao et al., 2005).  921 
The essential oil of Eugenia caryophyllata and its main active component, eugenol (Figure 3), 922 
were shown to have anti-inflammatory and pro-wound healing activity in an in vitro model due 923 
to the significant inhibition of many pro-inflammatory cytokines in dermal fibroblast cells (Han 924 
and Parker, 2017a). In another study, eugenol was shown to have a similar anti-inflammatory 925 
activity to the COX antagonist (indomethacin) and COX-2 selective antagonist (celecoxib) in 926 
a similar model (Daniel et al., 2009). 0.01% essential oil of Cuminum cyminum exhibited 927 
prominent anti-inflammatory activity by inhibiting inducible NO synthase (iNOS) and 928 
cyclooxygenase (COX-2) mRNA expression in LPS-stimulated RAW 2647 cells. Besides, 929 
0.01% essential oil of Cuminum cyminum decreased the levels of IL-1 and IL-6, which are 930 
important factors in inflammatory responses and chronic inflammatory diseases (Wei et al., 931 
2015).   932 
 933 
Citral, the main component of the essential oil of lemongrass, inhibits the production of TNF-934 
ά, IL-8, VCAM-1, and ICAM-1 in human umbilical vein endothelial cells and promotes wound 935 
healing through a tissue remodelling process (Song et al., 2016). The effects of Allium cepa 936 
and Pentadiplandra brazzeana essential oils were found to be 2 times greater than those of 937 
sodium diclofenac against heat denaturation of bovine serum albumin (BSA) (Foe et al., 2016).  938 
Lawsonia inermis was shown to have anti-inflammatory activity in in vivo and in vitro studies,  939 
(Bouhlali et al., 2016; Manivannan and Aeganathan, 2015; Chaibi et al., 2017). Flavonoids 940 
isolated from Lawsonia inermis reduced carrageenan-induced paw oedema and inflammation 941 
due to their antioxidant activity and their ability to modulate gene expression of cytokines and 942 
adhesion molecules (Castell, 2016). Similarly, the methanol extract of Lawsonia inermis and 943 
two alkaloids isolated from the methanol extract inhibited lipo-oxygenase enzyme by 944 
Figure 3: Structure of eugenol 
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decreasing the production of nitric oxide (NO) and pro-inflammatory cells and suppressing the 945 
biosynthesis of prostaglandins (Chaibi et al., 2017). Furthermore, Lawsonia inermis was 946 
reported to inhibit thermal induced tissue protein denaturation and promoted membrane 947 
stability by altering the electrostatic bond of hydrogen, and hydrophobic and disulphide bonds 948 
(Annavarapu et al., 2016).  949 
Similarly, Azadirachta indica was reported to have significant anti-inflammatory activity in 950 
both in vivo and in vitro studies. The chloroform extract and fractions reduced carrageenan-951 
induced oedema and granulation tissue formation in rats more powerfully than indomethacin. 952 
In addition, the fractions inhibited pro-inflammatory cells (IL-1 and TNF-α), COX-1 and COX-953 
2 in in vitro tests by inhibiting the interaction between  pathogen-associated molecular patterns 954 
(PAMPs) and toll receptors (TLRs), which impair the expression and production of pro-955 
inflammatory cells (Umar et al., 2014). Similarly, seed oil of Azadirachta indica inhibited 956 
oedema formation after carrageenan injection. The phytochemical constitutes of the oil, 957 
flavonoids, are shown to inhibit prostaglandin biosynthesis, endoperoxides, enzyme-like 958 
protein kinase and phosphodiesterase, which have key roles in inflammation (Naik et al., 2014).   959 
Bhosale et al. (2012) reported the anti-inflammatory activity of aqueous extract of Achyranthes 960 
aspera in carrageenan-induced paw oedema mice, which was attributable to flavonoids, 961 
alkaloids, saponins, and triterpenoids phytoconstituents found in the extracts. Similarly, 962 
Gokhale et al., (2002) reported anti-inflammatory activity of the ethanolic extract of 963 
Achyranthes aspera in Wistar rats due to the aforementioned plant constituents.  964 
For the in vivo anti-inflammatory assay, the most frequently used experimental model was 965 
carrageenan-induced paw oedema. This is a highly sensitive and reproducible test for non-966 
steroidal anti-inflammatory drugs and is established as a valid and widely used model to study 967 
new anti-inflammatory drugs and mechanisms of action (Dyzoyem and Bakowsky, 2017; 968 
Posadas et al., 2004). It is a useful method for detecting orally active anti-inflammatory agents 969 
and has significant predictive value for anti-inflammatory agents acting through mediators of 970 
acute inflammation (Dyzoyem and Bakowsky, 2017). It induces a biphasic oedema in the 971 
mouse paw.  The first phase (0-1h) is characterized by an acute and local inflammatory 972 
response which involves secretion of histamine, serotonin, and bradykinin. The second phase 973 
usually develops after 24h, and is characterized by more pronounced oedema with maximum 974 
effect in 48-72h. Prostaglandins and cytokines (IL-1ß, IL-6, IL-10, and TNF-ά) are 975 
inflammatory mediators involved in the second phase of oedema (Dyzoyem and Bakowsky, 976 
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2017; Morris, 2003; Posadas et al., 2004). The inflammatory response of carrageenan was 977 
quantified by measuring the circumference of oedema, which is maximal around 5h post-978 
carrageenan injection (Morris, 2003).  979 
ELISA was used for the in vitro anti-inflammatory assay to measure inflammatory biomarkers 980 
such as cytokines, chemokines, and metalloproteinases produced in the supernatants in LPS- 981 
stimulated cell culture. ELISA uses antibodies to differentiate epitopes of cytokines and uses 982 
them to capture and quantify an analyte of interest (cytokines from a cell culture supernatant) 983 
with a remarkable sensitivity (Chiswick et al., 2012; Rosengren et al., 2003). Similarly, 984 
Western blotting and gene expression quantification were used to measure the gene responsible 985 
for the production of inflammatory biomarkers.  986 
Wound healing is a complex process that includes a harmonized interaction between different 987 
immunological and biological systems (Velnar et al., 2009). It is divided into four phases. 988 
These are haemostasis, inflammation, proliferation and tissue remodelling, which are 989 
overlapping processes in time (Li et al., 2007; Singh et al., 2017). The first phase involves 990 
blood coagulation, haemostasis, and cellular events such as infiltration of leukocytes with 991 
different purposes in antimicrobial and cytokine release, which initiates the proliferative 992 
response for wound repair (Li et al., 2007). The second phase of wound healing is 993 
inflammation, whose aim is to prevent infection (Singh et al., 2017).  The third phase is 994 
characterized by fibroblast migration and deposition of newly synthesized extracellular matrix, 995 
acting as a replacement for the provisional network composed of fibrin and fibronectin. Finally, 996 
the remodelling phase is responsible for the development of new epithelium and final scar 997 
tissue formation (Velnar et al., 2009). 998 
Plant extracts have been reported for their wound healing activity, and promote wound healing 999 
through angiogenesis, activation of NF-κB, favouring pro-inflammatory cytokines, 1000 
upregulation of iNOS and alpha-1 type-1 collagen, fibroblast proliferation, and anti-oxidant 1001 
activity (Firdous, 2018).  1002 
The wound healing studies reported in this review tested the ability of plant extracts and 1003 
essential oils to contract wounds, reduce the period of epithelization, increase the tensile 1004 
strength of the wound (Dash et al., 2001; Tsala, 2016), influence cell migration and 1005 
proliferation (Freiesleben et al., 2017), and act through antioxidant and anti-microbial activities 1006 
(Asamenew et al., 2011), leading to tissue repair and restoration of function.  1007 
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In the study reported previously, the oil and resin of Commiphor aguidottii increased wound 1008 
contraction in rats, enhanced the proliferation of epithelial cells in incision wounds and 1009 
increased tensile strength in mice. The resins and oil were shown to increase collagen synthesis 1010 
as well as aid the cross-linking of proteins (Gebrehiwot et al., 2015).  1011 
In another study, incision and excision wounds of laboratory animals treated with 5% and 10% 1012 
methanol extracts of Achyranthes aspera showed faster healing, increased cellular proliferation 1013 
and shorter epithelization time in albino rats, which could be due to stimulation of cellular 1014 
proliferation and enhancement of collagen synthesis (Fikru et al., 2012). This report is in 1015 
agreement with the study reported by Barua et al., (2012) and Edwin et al., (2008) which 1016 
indicated that methanol and water extracts of A. Aspera promoted wound healing, likely due to 1017 
the secondary metabolites, triterpenes, known to promote wound healing process through their 1018 
astringent and antimicrobial property. Tannins promote capillary vasoconstriction, which 1019 
decreases vascular permeability and causes a local anti-inflammatory effect (Edwin et al., 1020 
2008). Phytochemical screening of the extracts revealed the presence of tannins and triterpenes 1021 
in the water and methanol extracts of A. Aspera (Barua et al., 2012; Edwin et al., 2008).  1022 
Mulisa and colleagues tested 4% and 10% (w/w) methanol extract (in ointment base) of Rumex 1023 
abyssinicus which significantly increased the percent wound closure in excision wounds; 1024 
shortened the epithelization time and increased the hydroxyproline content (Mulisa et al., 1025 
2015). In another study, Rumex abyssinicus was shown to possess antibacterial and anti-1026 
inflammatory activities; and the ability to regenerate epithelial cells, which might contribute to 1027 
wound healing (Getie et al., 2003).  1028 
Ointments prepared from a solvent fraction of Calpurnia aurea were shown to reduce the 1029 
epithelization time and increase wound contraction in mice, which might be attributed to the 1030 
secondary metabolites present in the fraction, such as terpenoids, tannins, alkaloids, saponins, 1031 
phenols and flavonoids that are known to promote wound healing via anti-bacterial and anti-1032 
inflammatory activities (Ayal et al., 2019). In the rat excision wound model, 10% ointment of 1033 
methanol extract of Croton macrostachyus showed the fastest and most complete wound 1034 
healing compared with the negative control. This activity may be due to its individual activity 1035 
or the combined activity of phytoconstituents such as anthraquinones, flavonoids, phytosterols, 1036 
polyphenols, saponins and tannins (Abraham et al., 2016).  1037 
The wound healing effect of the latex of Aloe megalacantha in an ointment form in excision 1038 
and incision wound models in rats was greater than that of the standard drug, nitrofurazone, 1039 
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which might be attributable to an individual or multiple phytochemical constituents 1040 
(Gebremeskel et al., 2018). This finding is consistent with other reports of wound healing 1041 
activity of other species of Aloe (Asamenew et al., 2011; Dat et al., 2014). Similarly, the 1042 
hydroalcoholic extract of Kalanchoe petitiana in an ointment base was shown to have better 1043 
wound healing activity than 0.2% nitrofurazone ointment.  1044 
A delay in wound healing was observed at higher concentrations of the extracts. There was an 1045 
enhanced rate of wound contraction and a reduction in healing time in animals treated with 1046 
ointment containing the methanol and aqueous fractions of Kalanchoe petitiana. The tensile 1047 
strength of 5% and 10% ointments of the crude extract treated groups were slightly greater than 1048 
those of the 0.2% nitrofurazone group. These activities might be due to the phytoconstituents, 1049 
especially flavonoids, which  play a great role in wound healing activity (Mekonnen et al., 1050 
2013). 1051 
The wound healing activity of Lawsonia inermis shown that henna leaf extracts had a high 1052 
healing rate due to secondary metabolites (Khaliq et al., 2018; Nayak et al., 2008).  Similar, 1053 
stem bark extracts of Azadirachta indica was shown to have a high level of hydroxyproline and 1054 
increased total protein content, which are indicators of wound healing. In addition, it increased 1055 
wound contraction, and DNA content in the scar tissue, which was a sign of cellular 1056 
proliferation (Maan et al., 2017).   1057 
Allophylus spicatus, Philenoptera cyanescens, Melanthera scanden, Ocimum gratissimum, and 1058 
Jasminum dichotomum were reported to increase proliferation and migration of cells in 3T3 1059 
fibroblasts cell lines (in vitro). The warm water extract of folium/fructus of Philenopter 1060 
acyanescens was shown to have the highest (100%) proliferation and migration rate compared 1061 
to the negative control groups, which was attributable to the active compounds rutin (quercetin-1062 
3-O- rutinoside) and quercetin-triglycoside, isolated from Philenoptera cyanescens. Both 1063 
compounds have anti-oxidant properties and are known in promoting cell proliferation 1064 
(Freiesleben et al., 2017). Figure 4.  1065 
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  1066 
Figure 4: Chemical structure of quercetin-3-O- rutinoside (A) and quercetin- 3,7,4’ -triglycoside (B) 1067 
The antioxidant properties of Aloe harlana Reynolds were evaluated using two assay methods, 1068 
DPPH and deoxyribose degradation assay. The latex and the compounds isolated from Aloe 1069 
harlana Reynolds correlated with the traditional use of the plant for the treatment of wounds, 1070 
infection and inflammatory diseases (Asamenew et al., 2011). Antioxidants are assumed to 1071 
help in controlling wound oxidative stress, which accelerates wound healing. They are 1072 
important mediators in regulating the damage that is potentially incurred by biological 1073 
molecules such as DNA, protein, lipids, and body tissue in the presence of reactive species 1074 
(Barku, 2019). 1075 
For the in vivo wound healing model, excision and incision wound models were the most 1076 
frequently used methods to test wound contraction, period of epithelization and wound tensile 1077 
strength. The wound breaking strength was measured using the incision method while collagen 1078 
estimation, period of epithelization and wound contraction were measured using the excision 1079 
method (Gautam et al., 2014). Among the in vitro wound assay methods, the wound scratch 1080 
assay was the most frequently used method and used alongside well-developed methods to 1081 
measure cell migration in vitro. A “wound gap” in a cell monolayer is created by scratching, 1082 
and the “healing” of this gap after treatment with plant extracts such as cell migration and 1083 
growth towards the centre of the gap is monitored and quantified (Chen, 2012). This is 1084 
particularly suitable for studies on the effects of cell interactions on cell migration, which 1085 
mimic in vivo cell migration and are compatible with imaging of live cells during migration to 1086 
monitor intracellular events (Liang et al., 2007). 1087 
 1088 
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5. Conclusion 1089 
 1090 
From the present study, it can be concluded that there are promising medicinal plant extracts 1091 
and compounds traditionally employed in Ethiopia that might be used as anti-inflammatory 1092 
and wound healing agents. Among these plants, Lawsonia inermis, Azadirachta indica, 1093 
Cuminum cyminum and Achyranthes Aspera are the most studied plant species for the 1094 
management of wound infection and inflammation, whereas Lawsonia inermis and 1095 
Azadirachta indica were the most commonly studied for wound healing.  1096 
In terms of effectiveness, methanol extract of Jasminium abyssinicum, chloroform extract of 1097 
Azadirachta indica, a flavonoid isolated from Lawsonia inermis and acetone extract of 1098 
Vernonia amygdalina are the most effective anti-inflammatory agents in animal models. 1099 
Similarly, methanol extracts of Lawsonia inermis, essential oil of Eugenia caryophyllata, 1100 
butanol fraction of Alnus nepalensis, Amaranthus dubius, Ocimum americanum, Vigna 1101 
unguiculata, and Zanthoxylum chalybeum are the most effective plant extracts in regulating 1102 
inflammatory and pro-inflammatory cells in in vitro models. On the other hand, ethanol extract 1103 
of Lawsonia inermis, aqueous extract of Azadirachta indica, 5% w/w ointment of Azadirachta 1104 
indica, extract and fractions of Calpurnia aurea in 10% ointment base, 10% (w/w) extract of 1105 
Croton macrostachyus in ointment base, leaf latex of Aloe megalacantha (5% and 10% in 1106 
ointment base) are the most effective plant materials for the management of wounds in animal 1107 
models.  1108 
6. Implications for future research and recommendations 1109 
 1110 
It is vital to systematically summarize, and document medicinal plants tested against a range 1111 
of diseases and used traditionally for treatment, and to test further their effectiveness against a 1112 
range of disease-related pathologies such as lymphoedema. Information about many medicinal 1113 
plants is fragmented, meaning that systematic compilation and synthesis are important. This 1114 
systematic review helped identify medicinal plants for the planned research aimed to develop 1115 
safe, effective and affordable alternatives for the management of tropical lymphoedema. It will 1116 
also create an opportunity for future research and practice by identifying and characterizing 1117 
compounds that could be developed into new standardized medicines. Medicinal plants hold 1118 
much promise for treating diseases, and there is a great potential for new drug discovery and 1119 
development. 1120 
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ANOVA - one-way analysis of variance 1122 
ARRIVE - Animal Research: Reporting of In Vivo Experiments 1123 
BHT – Butylhydroxytoluene 1124 
CAMARADES - Collaborative approach to Meta-Analysis and Review of Animal Data from 1125 
Experimental Studies 1126 
CC50 - Minimum dose that is toxic to 50 % of cells 1127 
CD4 - cluster of differentiation 4 1128 
CFU - Colony forming unit 1129 
Chi2 test – Chi square test 1130 
CI - Confidence interval  1131 
COX - Cyclooxygenase  1132 
DLA – dermatolymphangioadenitis 1133 
DMSO - Di-methyl-sulfoxide 1134 
DNA – Ribonucleic acid  1135 
DPPH - 2,2-Diphenyl-1-picrylhydrazyl 1136 
ED50 - Minimum dose that is effective to 50% of the population 1137 
ELISA - enzyme-linked immunosorbent assay 1138 
EMBASE- Excerpta Medical data BASE 1139 
GBD - Global Burden of Disease 1140 
GIVIMP - Guidance Document on Good In-Vitro Method Practices 1141 
GLP - Good laboratory practice  1142 
HDF3CGF- Primary human neonatal fibroblasts  1143 
HEK293 - human embryonic kidney 293  1144 
HMGB1- High mobility group box 1 protein 1145 
I2   test- I square test statistics 1146 
IC50 - half minimum inhibitory concertation  1147 
IFN-γ – interferon gamma 1148 
IL1 – Interleukin 1  1149 
IL10 - Interleukin 10 1150 
IL13 - Interleukin 13 1151 
IL1𝛽𝛽 – Interleukin one beta 1152 
IL4   - Interleukin 4  1153 
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IL6 - interleukin 6 1154 
IL8 - Interleukin-8 1155 
iNOS - Inducible nitric oxide synthase  1156 
IP-10 - Interferon gamma-induced protein 10  1157 
I-TAC - Interferon-inducible T-cell a chemoattractant  1158 
ITN - Iodonitrotetrazolium Chloride 1159 
JNK – Jun N-terminal kinase 1160 
LD50 - Lethal dose in 50% of the population 1161 
LD50 – Minimum dose that is lethal to 50% of the population 1162 
LF - Lymphatic filariasis 1163 
LOX - Lipoxygenase  1164 
LPS- Lipopolysaccharides  1165 
M2 - Macrophage type 2 1166 
MeSH - Medical Subject Heading  1167 
mg/ml – milli gram per ml 1168 
MIC- Minimum inhibitory concentration  1169 
MIG - monokine induced by gamma interferon 1170 
MLD - Manual lymphatic drainage  1171 
mRNA -Messenger Ribonucleic Acid 1172 
NF-kB p65 – nuclear factor kappa-light-chain-enhancer of activated B cells  1173 
NO - Nitric oxide 1174 
NSAIDs - Non-Steroidal anti-inflammatory drugs 1175 
NTD – Neglected Tropical Disease 1176 
OECD - Organization for Economic Cooperation and Development 1177 
PAMPs - pathogen- associated molecular patterns 1178 
PBS- phosphate buffered saline  1179 
PCR – Polymerase chain reaction  1180 
PICO – Population, Intervention, Comparator, Out-come 1181 
PRISMA-P - Preferred reporting items for systematic review and meta-analysis protocols  1182 
PROSPERO - International prospective register of systematic reviews 1183 
PUBMED/MEDLINE- National library of Medicine  1184 
RAW264.7 cells lines 1185 
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RoB – Risk of bias 1186 
SD – standard deviation 1187 
SPSS – Statistical package for social science 1188 
TGF-B1- transforming growth factor beta-1 1189 
TLRs - toll receptors 1190 
TM - Traditional medicine 1191 
TNF-alpha – Tumour necrosis factor alpha 1192 
TNFα - Interferon alpha 1193 
VCAM-1 - vascular cell adhesion molecule 1 1194 
WHO - World Health Organization 1195 
ZI – zone of inhibition 1196 
 1197 
Author contributions: DN, GD, EM, TB, MB, BAL and AF were involved in 1198 
conceptualization and design of the study, and in collection, analysis and interpretation of the 1199 
data. DN wrote the first draft of the manuscript and DN, GD, EM, TB, MB, BAL and AF 1200 
critically reviewed the manuscript for intellectual content. All authors have read and approved 1201 
the final manuscript.  1202 
Acknowledgments: We would like to thank CDT-Africa, Addis Ababa University and 1203 
Ethiopian Public Health Institute for organizing and sponsoring trainings on systematic review 1204 
and meta-analysis; and my special gratitude to Clare Callow, Grit Gansch and Manuela 1205 
McDermid for supporting us on work related to administration issues.  1206 
Funding: This research was funded by the National Institute for Health Research (NIHR) 1207 
Global Health Research Unit on NTDs at BSMS using UK aid from the UK Government to 1208 
support global health research. The views expressed in this publication are those of the author 1209 
(s) and not necessarily those of the NIHR or the UK Department for Health and Social Care. 1210 
Competing interests: none of the authors has any conflict of interest regarding this study.  1211 
 1212 
Ethical approval: not applicable 1213 
7. References 1214 
 1215 
Abdissa, H., 2011. Evaluation of anti-inflammatory and wound healing activities of the 80% 1216 
methanol fruit extracts of Dovyalis abyssinica A. Rich. in mice. Department of Pharmacology 1217 
and Therapeutic, Addis Ababa University, 13-53. 1218 
Page | 44 
 
Abraham, F.M., Ayele, T., Reta, T., Wondmagege, T., Tadesse, E., 2016. Experimental 1219 
evaluation of wound healing activity of Croton macrostachyus in rat. African J. Pharm. 1220 
Pharmacol. 10, 832–838. https://doi.org/10.5897/ajpp2015.4454 1221 
Adebayo, S.A., Dzoyem, J.P., Shai, L.J., Eloff, J.N., 2015. The anti-inflammatory and 1222 
antioxidant activity of 25 plant species used traditionally to treat pain in southern African. BMC 1223 
Complement. Altern. Med. 15, 1–10. https://doi.org/10.1186/s12906-015-0669-5 1224 
Adedapo, A.A., Aremu, O.J., Oyagbemi, A.A., 2014. Anti-Oxidant, anti-inflammatory and 1225 
antinociceptive properties of the acetone leaf extract of Vernonia Amygdalina in some 1226 
laboratory animals. Adv. Pharm. Bull. 4, 591–598. https://doi.org/10.5681/apb.2014.087 1227 
Adeyemi, O.O., Okpo, S.O., Ogunti, O.O., 2002. Analgesic and anti-inflammatory effects of 1228 
the aqueous extract of leaves of Persea americana Mill (Lauraceae). Fitoterapia 73, 375–380. 1229 
https://doi.org/10.1016/S0367-326X(02)00118-1 1230 
Al-niaimi, F., Cox, N., 2009. Cellulitis and lymphoedema: A vicious cycle. lymphoedema 4, 1231 
2–6. 1232 
Alemu, A., Tamiru, W., Nedi, T., Shibeshi, W., 2018. Analgesic and Anti-Inflammatory. 1233 
Complementary and Alternative Therapies for Inflammatory Diseases 2018, 1-8. Amoo, S.O., 1234 
Finnie, J.F., Van Staden, J., 2012. Acetylcholinesterase inhibition, antioxidant, anti-1235 
inflammatory, antimicrobial and phytochemical properties of huernia hystrix. Phyther. Res. 26, 1236 
639–645. https://doi.org/10.1002/ptr.3614 1237 
Annavarapu, T.R., Renuka, P., Akhil, P., Divya, P., Devi Priyanka, P., 2016. Evaluation of the 1238 
anti-inflammatory activity of combination of ethanol extracts of Azadirachta indica (Neem) 1239 
and Lawsonia inermis (Henna). Asian J. Pharm. Clin. Res. 9, 256–258. 1240 
Antonell, M.A., Astridou, M., Suchanová, B.B., Bernasconi C., Bostroem A-C., Bowe, G., et 1241 
al.,2018. Guidance Document on Good In Vitro Method Practices (GIVIMP), Organisation for 1242 
Economic Co-operation and Development. 1243 
Asamenew, G., Bisrat, D., Mazumder, A., Asres, K., 2011. In vitro antimicrobial and 1244 
antioxidant activities of anthrone and chromone from the latex of Aloe harlana reynolds. 1245 
Phyther. Res. 25, 1756–1760. https://doi.org/10.1002/ptr.3482 1246 
Asres, K., Gibbons, S., Hana, E., Bucar, F., 2005. Anti-inflammatory activity of extracts and a 1247 
saponin isolated from Melilotus elegans. Pharmazie 60, 310–312. 1248 
Ayal, G., Belay, A., Kahaliw, W., 2019. Evaluation of wound healing and anti-inflammatory 1249 
activity of the leaves of calpurnia aurea (ait.) Benth (fabaceae) in mice. Wound Med. 25, 29. 1250 
Badilla, B., Mora, G., Arthur, J., Emim, S., 1999. Anti-inflammatory activity of Urera baccifera 1251 
(Urticaceae) in Sprague-Dawley rats. Rev. biol. trop 47, 1–8. 1252 
Barbosa-Filho, J.M., Piuvezam, M, R., Moura1, M.D., Silva1, M.S., Karla, Lima1, V.B., Leitão 1253 
da-Cunha, E.V., Fechine, I.M., Orlando S. T., 2006. Anti-inflammatory activity of alkaloids: 1254 
A twenty-century review. Brazilian J. Pharmacogn. 16, 109–139. 1255 
Barku, V.Y.A., 2019. Wound Healing: Contributions from Plant Secondary Metabolite 1256 
Antioxidants, in: IntechOpen.  13. https://doi.org/http://dx.doi.org/10.5772/57353 1257 
Page | 45 
 
Barua, C.C., Talukdar, A., Begum, S.A., Pathak, D.C., Sarma, D.K., Borah, R.S., Gupta, A., 1258 
2012. In vivo wound-healing efficacy and antioxidant activity of Achyranthes aspera in 1259 
experimental burns. Pharm. Biol. 50, 892–899. https://doi.org/10.3109/13880209.2011.642885 1260 
Begashaw, B., Mishra, B., Tsegaw, A., Shewamene, Z., 2017. Methanol leaves extract Hibiscus 1261 
micranthus Linn exhibited antibacterial and wound healing activities. BMC Complement. 1262 
Altern. Med. 17, 1–12. https://doi.org/10.1186/s12906-017-1841-x 1263 
Bhosale, U.A., Yegnanarayan, R., Pophale, P., Somani, R., 2012. Effect of aqueous extracts of 1264 
Achyranthes aspera Linn. on experimental animal model for inflammation. Anc Sci Life 31, 1265 
202–206. https://doi.org/10.4103/0257-7941.107362 1266 
Bouhlali, E. dine T., Sellam, K., Bammou, M., Alem, C., Filali-Zehzouti, Y., 2016. In vitro 1267 
antioxidant and anti-inflammatory properties of selected moroccan medicinal plants. J. Appl. 1268 
Pharm. Sci. 6, 156–162. https://doi.org/10.7324/JAPS.2016.60525 1269 
Bribi, N., Algieri, F., Rodriguez-Nogales, A., Garrido-Mesa, J., Vezza, T., Maiza, F., Utrilla, 1270 
M.P., Rodriguez-Cabezas, M.E., Galvez, J., 2015. Antinociceptive and anti-inflammatory 1271 
effects of total alkaloid extract from fumaria capreolata. Evidence-based Complement. Altern. 1272 
Med. 2015, 1–7. https://doi.org/10.1155/2015/736895 1273 
Castell, M., 2016. Flavonoids, Inflammation and Immune System. Nutrients 8, 8–11. 1274 
https://doi.org/10.3390/nu8100659 1275 
Chaibi, R., Drine, S., Ferchichi, A, 2017. Chemical Study and Biological Activities of Various 1276 
Extracts from Lawsonia Inermis (Henna) Seeds. Acta Medica Mediterr 33, 195–201. 1277 
https://doi.org/10.19193/0393-6384 1278 
Chen, C.L., Zhang, D.D., 2014. Anti-inflammatory effects of 81 Chinese herb extracts and their 1279 
correlation with the characteristics of traditional Chinese medicine. Evidence-based 1280 
Complement. Altern. Med. 2014. https://doi.org/10.1155/2014/985176 1281 
Chen, Y., 2012. Scratch Wound Healing Assay. Bio-protocol 2, 3–5. 1282 
Chester, K., Zahiruddin, S., Ahmad, A., Khan, W., Paliwal, S., Ahmad, S., 2017. Anti-1283 
inflammatory Activity of Total Alkaloids from Hypecoum leptocarpum Hook. f. et Thoms. 1284 
Pharmacogn. Mag. 13, 179–188. https://doi.org/10.4103/pm.pm 1285 
Ching, F.P., Omogbai, E.K.I., Okpo, S.O., Ozolua, R.I., 2009. Antiinflammatory activity of 1286 
aqueous extract of Stereospermum kunthianum (cham, sandrine petit) stem bark in rats. Indian 1287 
J. Pharm. Sci. 71, 106–110. https://doi.org/10.4103/0250-474X.51943 1288 
Chiswick, E.L., Duffy, E., Japp, B., Remick, D., 2012. Detection and Quantification of 1289 
Cytokines and Other Biomarkers. Methods Mol Biol 844, 15–30. https://doi.org/10.1007/978-1290 
1-61779-527-5 1291 
Connor, A.M.O., Sargeant, J.M., 2014. Critical Appraisal of Studies Using Laboratory Animal 1292 
Models.  Institute for laboratory animal research journal 55 (3), 405-17. 1293 
https://doi.org/10.1093/ilar/ilu038 1294 
Daniel, A.N., Sartoretto, S.M., Schmidt, G., Caparroz-Assef, S.M., Bersani-Amado, C.A., 1295 
Cuman, R.K.N., 2009. Anti-inflammatory and antinociceptive activities of eugenol essential 1296 
Page | 46 
 
oil in experimental animal models. Brazilian J. Pharmacogn. 19, 212–217. 1297 
https://doi.org/10.1590/S0102-695X2009000200006 1298 
Dash, G.K., Suresh, P., Ganapaty, S., 2001. Studies on hypoglycaemic and wound healing 1299 
activities of Lantana camara Linn. J. Nat. Remedies 1, 105–110. 1300 
https://doi.org/10.18311/jnr/2001/16 1301 
Dat, A.D., Poon, F., Pham, K.B.T., Doust, J., 2014. Aloe vera for treating acute and chronic 1302 
wounds. Sao Paulo Med. J. 132, 382. https://doi.org/10.1590/1516-3180.20141326T1 1303 
Dilebo, J., Gebre-Mariam, T., Asres, K., 2011. Anti-inflammatory Activities of Extracts of 1304 
Some Traditionally Used Medicinal Plants in Ethiopia on Carrageenan-Induced Mouse Paw 1305 
Oedema. Ethiop. Pharm. J. 28. https://doi.org/10.4314/epj.v28i1.4 1306 
Dyzoyem, J.P., Bakowsky ,U., 2017. Carrageenan-Induced Paw Edema, in: Medicinal Spices 1307 
and Vegetables from Africa. 1st edition. 169 1308 
Edwin, S., Jarald, E.E., Deb, L., Jain, A., Kinger, H., Dutt, K.R., Raj, A.A., 2008. Wound 1309 
healing and antioxidant activity of Achyranthes aspera. Pharm. Biol. 46, 824–828. 1310 
https://doi.org/10.1080/13880200802366645 1311 
Effects of 80% Methanol Extract of Leonotis ocymifolia (Burm.f.) Iwarsson Leaves in Rodent 1312 
Models. Evidence-based Complement. Altern. Med. 2018. 1313 
https://doi.org/10.1155/2018/1614793 1314 
El-Shanawany, M.A., Sayed, H.M., Ibrahim, S.R.M., Fayed, M.A.A., 2014. Chemical 1315 
constituents, anti-inflammatory, and antioxidant activities of Anisotes trisulcus. Bull. Fac. 1316 
Pharmacy, Cairo University 52, 9–14. https://doi.org/10.1016/j.bfopcu.2014.02.004 1317 
Fikru, A., Makonnen, E., Eguale, T., Debella, A., Abie, G., 2012. Evaluation of in vivo wound 1318 
healing activity of methanol extract of Achyranthes aspera L. J. Ethnopharmacol. 143, 469–1319 
474. https://doi.org/10.1016/j.jep.2012.06.049 1320 
Firdous, S. M., Sautya, D., 2018. Medicinal plants with wound healing potential. Bangladesh 1321 
J Pharmacol 13, 41–52. https://doi.org/10.3329/bjp.v13i1.32646 1322 
Freiesleben, S.H., Soelberg, J., Nyberg, N.T., Jäger, A.K., 2017. Determination of the wound 1323 
healing potentials of medicinal plants historically used in Ghana. Evidence-based Complement. 1324 
Altern. Med. 2017, 6. https://doi.org/10.1155/2017/9480791 1325 
Gautam, M.K., Purohit, V., Agarwal, M., Singh, A., Goel, R.K., 2014. In vivo healing potential 1326 
of aegle marmelos in excision, incision, and dead space wound models. Sci. World J. 2014. 1327 
https://doi.org/10.1155/2014/740107 1328 
Gebrehiwot, M., Asres, K., Bisrat, D., Mazumder, A., Lindemann, P., Bucar, F., 2015. 1329 
Evaluation of the wound healing property of Commiphora guidottii Chiov. ex. Guid. BMC 1330 
Complement. Altern. Med. 15, 1–11. https://doi.org/10.1186/s12906-015-0813-2 1331 
Gebremeskel, L., Bhoumik, D., Sibhat, G.G., Tuem, K.B., 2018. In Vivo Wound Healing and 1332 
Anti-Inflammatory Activities of Leaf Latex of Aloe megalacantha Baker (Xanthorrhoeaceae). 1333 
Evidence-Based Complement. Altern. Med. 2018, 1–7. https://doi.org/10.1155/2018/5037912 1334 
George, G., Robless, P., Jane, L., 2007. Lymphoedema. Surgery 26, 2–5. 1335 
Page | 47 
 
Getie, M., Gebre-Mariam, T., Rietz, R., Höhne, C., Huschka, C., Schmidtke, M., Abate, A., 1336 
Neubert, R.H.H., 2003. Evaluation of the anti-microbial and anti-inflammatory activities of the 1337 
medicinal plants Dodonaea viscosa, Rumex nervosus and Rumex abyssinicus. Fitoterapia 74, 1338 
139–143. https://doi.org/10.1016/S0367-326X(02)00315-5 1339 
Gokhale, A.B., Damre, A.S., Kulkarni, K.R., Saraf, M.N., 2002. Preliminary evaluation of anti-1340 
inflammatory and anti-arthritic activity of S. lappa, A. speciosa and A. aspera. Phytomedicine 1341 
9, 433–437. 1342 
Hamad, K.M., Sabry, M.M., Elgayed, S.H., El Shabrawy, A.R., El-Fishawy, A.M., Abdel 1343 
Jaleel, G.A., 2019. Anti-inflammatory and phytochemical evaluation of Combretum aculeatum 1344 
Vent growing in Sudan. J. Ethnopharmacol. 242. https://doi.org/10.1016/j.jep.2019.112052 1345 
Han, X., Parker, T.L., 2017a. Anti-inflammatory activity of clove (Eugenia caryophyllata) 1346 
essential oil in human dermal fibroblasts. Pharm. Biol. 55, 1619–1622. 1347 
https://doi.org/10.1080/13880209.2017.1314513 1348 
Han, X., Parker, T.L., 2017b. Lemongrass (Cymbopogon flexuosus) essential oil demonstrated 1349 
anti-inflammatory effect in pre-inflamed human dermal fibroblasts. Biochim. Open 4, 107–1350 
111. https://doi.org/10.1016/j.biopen.2017.03.004 1351 
Hassan, M.M, Khan, S.A., Shaikat, A.H., Hossain, E., Hoque, A., Ullah, H., Islam, S., 2013. 1352 
Analgesic and anti-inflammatory effects of ethanol extracted leaves of selected medicinal 1353 
plants in animal model. Vet. World 6, 68–71. https://doi.org/10.5455/vetworld.2013.68-71 1354 
 1355 
Hawaze, S., Deti, H., Suleman, S., 2013. Wound healing activity of the methanol extracts of 1356 
Clematis species indigenous to Ethiopia. Int. J. Green Pharm. 7, 304–308. 1357 
https://doi.org/10.4103/0973-8258.122058 1358 
Hooijmans, C.R., Rovers, M.M., Vries, R.B.M. De, Leenaars, M., Ritskes-hoitinga, M., 1359 
Langendam, M.W., 2014. SYRCLE’ s risk of bias tool for animal studies. BMC Med. Res. 1360 
Methodol. 14, 1–9. 1361 
Hopkins, A. L., Mason, J. S., Overington, J.P., 2006. Can we rationally design promiscuous 1362 
drugs? Curr. Opin. Struct. Biol. 16, 127–136. https://doi.org/10.1016/j.sbi.2006.01.013 1363 
Hosseinzadeh, H., Khoshdel, M., Ghorbani, M., 2011. Antinociceptive, Anti-inflammatory 1364 
Effects and Acute Toxicity of Aqueous and Ethanolic Extracts of Myrtus communis L. Aerial 1365 
Parts in Mice. JAMS J. Acupunct. Meridian Stud. 4, 242–247. 1366 
https://doi.org/10.1016/j.jams.2011.09.015 1367 
Joseph C. Maroon, Jeffrey W. Bost, and A.M., 2010. Natural anti-inflammatory agents for pain 1368 
relief. Surg. Neurol. Int. 1, 80. https://doi.org/10.4103/2152-7806.73804 1369 
Jullien, P., Somé, A., Brantus, P., Bougma, R.W., Bamba, I., Kyelem, D., 2011. Efficacy of 1370 
home-based lymphoedema management in reducing acute attacks in subjects with lymphatic 1371 
filariasis in Burkina Faso. Acta Trop. 120S, S55– S61. 1372 
https://doi.org/10.1016/j.actatropica.2011.03.007 1373 
Page | 48 
 
Kaushik, D., Kumar, A., Kaushik, P., Rana, A.C., 2012. Analgesic and anti-inflammatory 1374 
activity of pinus roxburghii sarg. Adv. Pharmacol. Sci. 2012. 1375 
https://doi.org/10.1155/2012/245431 1376 
Khaliq, F.A., Raza, M., Hassan, S.U., Iqbal, J., Aslam, A., Aun, M., Ansari, M.T., Zahid, S., 1377 
2018. Formulation, Characterization and Evaluation of in vivo Wound Healing Potential of 1378 
Lawsone Ointment. Am. J. Adv. Drug Deliv. 06. https://doi.org/10.21767/2321-547x.1000026 1379 
Khedir, S. Ben, Mzid, M., Bardaa, S., Moalla, D., Sahnoun, Z., Rebai, T., 2016. In vivo 1380 
evaluation of the anti-inflammatory effect of pistacia lentiscus fruit oil and its effects on 1381 
oxidative stress. Evidence-based Complement. Altern. Med. 2016, 1–7. 1382 
https://doi.org/10.1155/2016/6108203 1383 
Kilkenny, C., Browne, W.J., Cuthill, I.C., Emerson, M., Altman, D.G., 2010. Improving 1384 
Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research. 1385 
Plos Biol. 8, 6–10. https://doi.org/10.1371/journal.pbio.1000412 1386 
Krithikadatta, J., Gopikrishna, V., Datta, M., Editor, A., Nadu, T., Nadu, T., Nadu, T., Editor, 1387 
A., Nadu, T., 2019. CRIS Guidelines (Checklist for Reporting In-vitro Studies): A concept note 1388 
on the need for standardized guidelines for improving quality and transparency in reporting in-1389 
vitro studies in experimental dental. J Conserv Dent 17, 301–304. 1390 
https://doi.org/10.4103/0972-0707.136338 1391 
Li, J., Chen, J., Kirsner, R., 2007. Pathophysiology of acute wound healing. Clin. Dermatol. 1392 
25, 9–18. https://doi.org/10.1016/j.clindermatol.2006.09.007 1393 
Liang, C. C., Park, A. Y., Guan, J.L., 2007. In vitro scratch assay: A convenient and 1394 
inexpensive method for analysis of cell migration in vitro. Nat. Protoc. 2, 329–333. 1395 
https://doi.org/10.1038/nprot.2007.30 1396 
Lisovoski, F., 1986. Lymphoedema. Lancet 688–689. 1397 
Lulekal, E., Rondevaldova, J., Bernaskova, E., Cepkova, J., Asfaw, Z., Kelbessa, E., Kokoska, 1398 
L., Van Damme, P., 2014. Antimicrobial activity of traditional medicinal plants from Ankober 1399 
District, North Shewa Zone, Amhara Region, Ethiopia. Pharm. Biol. 52, 614–620. 1400 
https://doi.org/10.3109/13880209.2013.858362 1401 
Maan, P., Yadav, K.S., Yadav, N.P., 2017. Wound Healing Activity of Azadirachta indica A . 1402 
Juss Stem Bark in Mice Plant materials. Pharmacogn. Mag. 13, 316–320. 1403 
https://doi.org/10.4103/0973-1296.210163 1404 
Manivannan R., Aeganathan R., P.K., 2015. Anti-microbial and anti-inflammatory flavonoid 1405 
constituents from the leaves of Lawsonia inermis. J. Phytopharm.  4, 212–216. 1406 
Marzouk, B., Marzouk, Z., Haloui, E., Fenina, N., Bouraoui, A., Aouni, M., 2010. Screening 1407 
of analgesic and anti-inflammatory activities of Citrullus colocynthis from southern Tunisia. J. 1408 
Ethnopharmacol. 128, 15–19. https://doi.org/10.1016/j.jep.2009.11.027 1409 
Masresha, B., Makonnen, E., Debella, A., 2012. In vivo anti-inflammatory activities of 1410 
Ocimum suave in mice. J. Ethnopharmacol. 142, 201–205. 1411 
https://doi.org/10.1016/j.jep.2012.04.041 1412 
Page | 49 
 
Mathew, N., Misra-Bhattacharya, S., Perumal, V., Muthuswamy, K., 2008. Antifilarial lead 1413 
molecules isolated from Trachyspermum ammi. Molecules 13, 2156–2168. 1414 
https://doi.org/10.3390/molecules13092156 1415 
Mechesso, A.F., Tadese, A., Tesfaye, R., Tamiru, W., 2016. Experimental evaluation of wound 1416 
healing activity of Croton macrostachyus in rat Experimental evaluation of wound healing 1417 
activity of Croton macrostachyus in rat. African J. Pharm. Pharmacol. 10, 832–838. 1418 
https://doi.org/10.5897/AJPP2015.4454 1419 
Mekonnen, A., Sidamo, T., Asres, K., Engidawork, E., 2013. In vivo wound healing activity 1420 
and phytochemical screening of the crude extract and various fractions of Kalanchoe petitiana 1421 
A. Rich (Crassulaceae) leaves in mice. J. Ethnopharmacol. 145, 638–646. 1422 
https://doi.org/10.1016/j.jep.2012.12.002 1423 
Mequanint, W., Makonnen, E., Urga, K., 2011. In vivo anti-inflammatory activities of leaf 1424 
extracts of Ocimum lamiifolium in mice model. J. Ethnopharmacol. 134, 32–36. 1425 
https://doi.org/10.1016/j.jep.2010.11.051 1426 
Mohamed, D.A., Mahmoud, E.A., Abdel-moniem, S., Hassan, M., 2013. Anti-Inflammatory 1427 
and Anti-Arthritic Activity Of Some Spices Extracts On Adjuvant induced arthritis in rats. J. 1428 
Appl. Sci. Res. 9, 5303–5312. 1429 
Mohammed, M.S., Osman, W.J.A., Garelnabi, E.A.E., Osman, Z., Osman, B., Khalid, H.S., 1430 
Mohamed, M.A., Osman, J.A., 2014. Secondary metabolites as anti-inflammatory agents. J. 1431 
Phytopharm. 3, 275–285. 1432 
Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, et al., 2016. Preferred 1433 
reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 1434 
statement. Rev. Esp. Nutr. Humana y Diet. 20, 148–160. https://doi.org/10.1186/2046-4053-4-1435 
1 1436 
Morris, C.J., 2003. Carrageenan-Induced Paw Edema in the Rat and Mouse, in: P. G. Winyard 1437 
and D. A. Willoughby (Ed.), Methods in Molecular Biology: Inflammation Protocols. Humana 1438 
Press Inc, Totowa, New Jersey, pp. 115–121. 1439 
Mota, M.L.R., Thomas, G., Filho, J.M.B., 1985. Anti-inflammatory actions of Tannins isoalted 1440 
from the bark of Anacardium occidentale. J. Ethnopharmacol. 13, 289–300. 1441 
Mulisa, E., Asres, K., Engidawork, E., 2015. Evaluation of wound healing and anti-1442 
inflammatory activity of the rhizomes of Rumex abyssinicus J. (Polygonaceae) in mice. BMC 1443 
Complement. Altern. Med. 15, 1–10. https://doi.org/10.1186/s12906-015-0878-y 1444 
Nagesh, H.N., Basavanna, P.L., Kishore, M.S., 2015. Evaluation of wound healing activity of 1445 
ethanolic extract of Azadirachta Indica leaves on incision and excision wound models in Wister 1446 
albino rats. Int. J. Basic Clin. Pharmacol. 4, 1178–1182. https://doi.org/10.18203/2319-1447 
2003.ijbcp20151354 1448 
Naik, M.R., Bhattacharya, A., Behera, R., Agrawal, D., Dehury, S., Kumar, S., 2014. Study of 1449 
anti-inflammatory effect of neem seed oil (Azadirachta indica) on infected albino rats. J. Heal. 1450 
Res. Rev. 1, 66–69. https://doi.org/10.4103/2394-2010.153880 1451 
Page | 50 
 
Nayak BS, Isito G, Davis EM, Pillai, G.K., 2008. The Evidence based Wound Healing Activity 1452 
of Lawsonia inermis Linn. Phyther. Res. 22, 544–549. https://doi.org/10.1002/ptr 1453 
Ndoye Foe, F.M.C., Tchinang, T.F.K., Nyegue, A.M., Abdou, J.P., Yaya, A.J.G., Tchinda, 1454 
A.T., Essame, J.L.O., Etoa, F.X., 2016. Chemical composition, in vitro antioxidant and anti-1455 
inflammatory properties of essential oils of four dietary and medicinal plants from Cameroon. 1456 
BMC Complement. Altern. Med. 16, 1–12. https://doi.org/10.1186/s12906-016-1096-y 1457 
Nigussie, D., Legesse, B.A., Davey, G., Fekadu, A., 2020. Ethiopian medicinal plants used for 1458 
inflammatory, wound healing or anti-infective activities: protocol for systematic literature 1459 
review and meta--analysis. BMJ open Sci. 4, 1–8. https://doi.org/10.1136/bmjos-2020-100064 1460 
Pereira, L.D.P., Emanuella, K., Silva, S., Silva, O., Assreuy, A.M.S., Pereira, M.G., 2012. Anti-1461 
inflammatory polysaccharides of Azadirachta indica seed tegument. Rev. Bras. Farm. Braz. J. 1462 
Pharmacogn 22, 617–622. 1463 
Posadas, I., Bucci, M., Roviezzo, F., Rossi, A., Parente, L., Sautebin, L., Cirino, G., 2004. 1464 
Carrageenan-induced mouse paw oedema is biphasic, age-weight dependent and displays 1465 
differential nitric oxide cyclooxygenase-2 expression. Br. J. Pharmacol. 142, 331–338. 1466 
https://doi.org/10.1038/sj.bjp.0705650 1467 
Vijayaraj, R., Kumaran N.S., 2018. Protective effect of Lawsonia inermis Linn. on chronic 1468 
inflammation in rats. Int. J. Green Pharm. 12, S549. https://doi.org/10.1161/01.STR.9.5.524 1469 
Rao, Y.K., Fang, S.H., Tzeng, Y.M., 2005. Anti-inflammatory activities of flavonoids isolated 1470 
from Caesalpinia pulcherrima. J. Ethnopharmacol. 100, 249–253. 1471 
https://doi.org/10.1016/j.jep.2005.02.039 1472 
Rosengren, S., Firestein, G.S., Boyle, D.L., 2003. Measurement of Inflammatory Biomarkers 1473 
in Synovial Tissue Extracts by Enzyme-Linked Immunosorbent Assay 10, 1002–1010. 1474 
https://doi.org/10.1128/CDLI.10.6.1002 1475 
UKEssays., 2018. Anti-inflammatory Profile of Alnus Nepalensis Leaves. Retrieved from 1476 
https://www.ukessays.com/essays/biology/antiinflammatory-profile-alnus-nepalensis-1477 
2646.php?vref=1 1478 
Schumacher, M., Cerella, C., 2011. Anti-inflammatory, pro-apoptotic, and anti-proliferative 1479 
effects of a methanolic neem (Azadirachta indica) leaf extract are mediated via modulation of 1480 
the nuclear factor-jB pathway. Genes Nutr 6, 149–160. https://doi.org/10.1007/s12263-010-1481 
0194-6 1482 
Sewuye, W., Asres, K., 2009. In Vivo Anti-inflammatory and Antinociceptive Activities of 1483 
Extracts of Rosa abyssinica and Salvia nilotica. Ethiop. Pharm. J. 26. 1484 
https://doi.org/10.4314/epj.v26i2.43038 1485 
Sharma, V., Rajani, G., 2011. Evaluation of Caesalpinia pulcherrima Linn. for anti-1486 
inflammatory and antiulcer activities. Indian J. Pharmacol. 43, 168–171. 1487 
https://doi.org/10.4103/0253-7613.77354 1488 
Pan, Si-Y., Zhou, Shu-F., Gao, Si-H., Zhi-Ling Yu, Zhi-L., Zhang Shuo-F, Tang, Min-K., Sun, 1489 
Jian-N., Ma, Dik-L., Han, Yi-F., Fong, Wang-F., Ko, Kam-M., 2013. New Perspectives on 1490 
Page | 51 
 
How to Discover Drugs from Herbal Medicines: CAM’s Outstanding Contribution to Modern 1491 
Therapeutics. Evidence-Based Complement. Altern. Med. 2013, 25. 1492 
Singh, S., Young, A., McNaught, C.E., 2017. The physiology of wound healing. Surgery 35, 1493 
473–477. https://doi.org/10.1016/j.mpsur.2017.06.004 1494 
Song, Y., Zhao, H., Liu, J., Fang, C., Miao, R., 2016. Effects of Citral on Lipopolysaccharide-1495 
Induced Inflammation in Human Umbilical Vein Endothelial Cells. Inflammation 39, 663–671. 1496 
https://doi.org/10.1007/s10753-015-0292-0 1497 
Tadiwos, Y., Nedi, T., Engidawork, E., 2017. Analgesic and anti-inflammatory activities of 1498 
80% methanol root extract of Jasminum abyssinicum Hochst. ex. Dc. (Oleaceae) in mice. J. 1499 
Ethnopharmacol. 202, 281–289. https://doi.org/10.1016/j.jep.2017.02.036 1500 
Tamrat, Y., Nedi, T., Assefa, S., Teklehaymanot, T., Shibeshi, W., 2017. Anti-inflammatory 1501 
and analgesic activities of solvent fractions of the leaves of Moringa stenopetala Bak. 1502 
(Moringaceae) in mice models. BMC Complement. Altern. Med. 17, 1–10. 1503 
https://doi.org/10.1186/s12906-017-1982-y 1504 
Tomy, M.J., Dileep, K. V., Prasanth, S., Preethidan, D.S., Sabu, A., Sadasivan, C., Haridas, 1505 
M., 2014. Cuminaldehyde as a Lipoxygenase Inhibitor: In Vitro and In Silico Validation. Appl. 1506 
Biochem. Biotechnol. 174, 388–397. https://doi.org/10.1007/s12010-014-1066-0 1507 
Tsala, D.E., 2016. In Vivo Wound Healing Effect of Water Extract of Stereospernum 1508 
kunthianum Stem-Bark. J. Med. Herbs Ethnomedicine 2. 1509 
https://doi.org/10.19071/jmhe.2016.v2.2929 1510 
Tufts, H.R., Harris, C.S., Bukania, Z.N., Johns, T., 2015. Antioxidant and Anti-Inflammatory 1511 
Activities of Kenyan Leafy Green Vegetables, Wild Fruits, and Medicinal Plants with Potential 1512 
Relevance for Kwashiorkor. Evidence-based Complement. Altern. Med. 1513 
https://doi.org/10.1155/2015/807158 1514 
Umar, M.I., Asmawi, M.Z., Sadikun, A., Majid, A., Atangwho, I.J., Ahamed, M.B.K., Ahmad, 1515 
A., Majid, A., Atangwho, I.J., Ahamed, M.B.K., Altaf, R., Ahmad, A., Umar, M.I., Asmawi, 1516 
M.Z., Sadikun, A., Majid, A.M.S.A., 2014. Multi-constituent synergism is responsible for anti-1517 
inflammatory effect of Azadirachta indica leaf extract Multi-constituent synergism is 1518 
responsible for anti-inflammatory effect of Azadirachta indica leaf extract. Pharm. Biol. 52, 1519 
1411–1422. https://doi.org/10.3109/13880209.2014.895017 1520 
Velnar, T., Bailey, T., Smrkolj, V., 2009. The wound healing process: An overview of the 1521 
cellular and molecular mechanisms. J. Int. Med. Res. 37, 1528–1542. 1522 
https://doi.org/10.1177/147323000903700531 1523 
Wei, J., Zhang, X., Bi, Y., Miao, R., Zhang, Z., Su, H., 2015. Anti-Inflammatory Effects of 1524 
Cumin Essential Oil by Blocking JNK, ERK, and NF- B Signaling Pathways in LPS-Stimulated 1525 
RAW 264.7 Cells. Evidence-based Complement. Altern. Med. 2015. 1526 
https://doi.org/10.1155/2015/474509 1527 
Wolde-Mariam, M., Yarlagadda, R., Asres, K., 2013. In vivo anti-inflammatory and 1528 
antinociceptive activities of the aerial part extract of Dicliptera laxata. Int. J. Green Pharm. 7, 1529 
216–223. https://doi.org/10.4103/0973-8258.120232 1530 
Page | 52 
 
Yonathan, M., Asres, K., Assefa, A., Bucar, F., 2006. In vivo anti-inflammatory and anti-1531 
nociceptive activities of Cheilanthes farinosa. J. Ethnopharmacol. 108, 462–470. 1532 
https://doi.org/10.1016/j.jep.2006.06.006 1533 
 1534 
